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Insights Into Functional Noncoding Rna Elements Through The Analysis Of 
Human Genetic Variation 
Abstract 
Most of the human genome is noncoding but knowing how and when genetic variation in noncoding 
regions of the genome can impact biology and disease susceptibility remains challenging. Here, we apply 
an integrated genomics approach towards understanding and elucidating new patterns of functional 
genetic variation in untranslated regions of protein-coding messenger RNAs. 
G-quadruplex (G4) sequences are abundant in untranslated regions (UTRs) of human messenger RNAs, 
but their functional importance remains unclear. In Part 1 of this dissertation, we integrate multiple 
sources of genetic and genomic data to show that putative G-quadruplex forming sequences (pG4) in 5’ 
and 3’ UTRs are selectively constrained and enriched for cis-eQTLs and RNA-binding protein (RBP) 
interactions. Using over 15,000 whole genome sequences, we find evidence of strong negative selection 
acting on central guanines of UTR pG4s. At multiple GWAS-implicated SNPs within pG4 UTR sequences, 
we find robust allelic imbalance in gene expression across diverse tissue contexts in GTEx, suggesting 
that variants affecting G4 formation in UTRs may also contribute to phenotypic variation. Our results 
establish UTR G4s as important cis-regulatory elements and point to a link between disruption of UTR 
pG4 and disease. 
In Part 2 of this dissertation, we examine patterns of selective pressure in non-canonical open reading 
frames (ncORFs) mapped throughout the human genome. Ribosome-profiling has uncovered pervasive 
translation in ncORFs, however the biological significance of this phenomenon remains unclear. Using 
genetic variation from 71,702 human genomes, we assess patterns of selection in translated upstream 
open reading frames (uORFs) in 5’UTRs. We show that uORF variants introducing new stop codons, or 
strengthening existing stop codons, are under strong negative selection comparable to protein-coding 
missense variants. Using these variants, we map and validate new gene-disease associations in two 
independent biobanks containing exome sequencing from 10,900 and 32,268 individuals, respectively, 
and elucidate their impact of protein expression in human cells. Our results suggest new mechanisms 
relating uORF variation to reduced protein expression and demonstrate that translation at uORFs is 
genetically constrained in 50% of human genes. 
Together, these studies help emphasize the importance of noncoding RNA regulatory elements in 
mediating post-transcriptional regulation of gene expression and illuminate new patterns of functional 
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INSIGHTS INTO FUNCTIONAL NONCODING RNA ELEMENTS THROUGH THE ANALYSIS OF 
HUMAN GENETIC VARIATION 
David S.M. Lee 
Yoseph Barash 
Louis R. Ghanem 
Most of the human genome is noncoding but knowing how and when genetic variation in 
noncoding regions of the genome can impact biology and disease susceptibility remains 
challenging. Here, we apply an integrated genomics approach towards understanding and 
elucidating new patterns of functional genetic variation in untranslated regions of protein-coding 
messenger RNAs.  
 
G-quadruplex (G4) sequences are abundant in untranslated regions (UTRs) of human messenger 
RNAs, but their functional importance remains unclear. In Part 1 of this dissertation, we integrate 
multiple sources of genetic and genomic data to show that putative G-quadruplex forming 
sequences (pG4) in 5’ and 3’ UTRs are selectively constrained and enriched for cis-eQTLs and 
RNA-binding protein (RBP) interactions. Using over 15,000 whole genome sequences, we find 
evidence of strong negative selection acting on central guanines of UTR pG4s. At multiple 
GWAS-implicated SNPs within pG4 UTR sequences, we find robust allelic imbalance in gene 
expression across diverse tissue contexts in GTEx, suggesting that variants affecting G4 
formation in UTRs may also contribute to phenotypic variation. Our results establish UTR G4s as 
important cis-regulatory elements and point to a link between disruption of UTR pG4 and disease. 
 
In Part 2 of this dissertation, we examine patterns of selective pressure in non-canonical open 
reading frames (ncORFs) mapped throughout the human genome. Ribosome-profiling has 
uncovered pervasive translation in ncORFs, however the biological significance of this 
phenomenon remains unclear. Using genetic variation from 71,702 human genomes, we assess 
patterns of selection in translated upstream open reading frames (uORFs) in 5’UTRs. We show 
that uORF variants introducing new stop codons, or strengthening existing stop codons, are 
under strong negative selection comparable to protein-coding missense variants. Using these 
variants, we map and validate new gene-disease associations in two independent biobanks 
containing exome sequencing from 10,900 and 32,268 individuals, respectively, and elucidate 
their impact of protein expression in human cells. Our results suggest new mechanisms relating 
uORF variation to reduced protein expression and demonstrate that translation at uORFs is 
genetically constrained in 50% of human genes.  
 
Together, these studies help emphasize the importance of noncoding RNA regulatory elements in 
mediating post-transcriptional regulation of gene expression and illuminate new patterns of 
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CHAPTER 1: THE REGULATORY RENAISSANCE 
 
1.1: How many genes? 
In 1999 the New York Times published estimates from scientists at the Incyte Corporation that 
the human genome contained approximately 140,000 genes. This represented a ~40% increase 
over the consensus estimate by many researchers at the time, with most previous estimates 
falling between 50,000-100,000. Many assumed that more complex organisms, like humans, 
necessitated a greater number of genes to support their biological complexity.  As early as 1951 it 
had been observed that genome size appeared to increase with organismal complexity from 
invertebrates to vertebrates [1]. However, when the first working draft human genome was 
published in 2001, many were surprised to find evidence supporting the existence of only 30-
40,000 protein coding genes [2]. Three years later, this estimate was further reduced to 21,000 - 
almost 20% less than in the zebrafish genome (~26,000) [3,4]. The paucity of protein coding 
genes in the draft human genome challenged the view that more complex organisms encoded 
more proteins in their genomes, and raised an important question: What was the source of 
human biological complexity? 
The discrepancy between perceived organismal complexity and the number of protein coding 
genes came to be known as the “G-value Paradox”. One proposed resolution to this paradox 
hypothesized that biological complexity more likely arose from a milieu of regulatory interactions 
between a limited set of protein-coding genes rather simply encoding more genes in the genome. 
These ideas were pioneered by Roy Britten and Eric Davidson in a 1969 essay published in 
Science [5], writing that:  
Nonetheless, it seems unlikely that the 30-fold increase from poriferan to mammal can be 
attributed to a 30-fold increase in the number of producer [protein-coding] genes … Quite 
possibly, the principal difference between a poriferan and a mammal could lie in the 
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degree of integrated cellular activity, and thus in a vastly increased complexity of 
regulation rather than a vastly increased number of producer genes. 
 
We now recognize that substantial biological complexity arises through multiple layers of 
regulation - from the intracellular processes that govern gene expression and alternative splicing, 
to tissue-level and whole-organism levels of regulation that contribute to physiology and 
pathology. Many diseases result from otherwise protective physiologic processes - including 
fibrosis, inflammation, and immune activation - that become co-opted and dysregulated to 
produce pathology. Understanding the contribution of our genetics to how these processes 
become dysregulated can not only help expand our appreciation of disease biology, but also 
inform new targeted approaches towards therapeutic development.   
 
1.2: Genetic variation and common disease 
A crucial motivation for sequencing the human genome was to better understand the relationship 
between genes and disease. Shortly after the first draft human sequence was completed, the 
International HapMap was formed to create a database of common single nucleotide 
polymorphisms (SNPs) across diverse human populations [6]. The formation of this database 
facilitated a wave of genome wide association studies (GWAS) through which researchers sought 
to associate common genetic variants with numerous human phenotypes [7]. A typical GWAS 
required genotyping large cohorts of individuals at 300,000 - 5 million SNPs selected for their 
ability to provide broad coverage across the human genome by being in linkage disequilibrium 
with as many nearby genetic variants as possible [8]. Each genotyped SNP therefore represented 
a block of commonly co-inherited genetic variants, all in linkage disequilibrium. Association tests 
were then performed between genotyped SNPs and phenotypes of interest to determine whether 
specific alleles at these variants were. Phenotypes of interest could include true disease cases 
3 
 
versus controls, or with continuous traits like height or QT interval. When statistically significant 
associations were uncovered, discriminating between one or multiple true causal variants among 
co-inherited blocks of SNPs required additional fine-mapping and functional studies. Since most 
genetic variants uncovered through association studies resided in noncoding regions of the 
genome, the relationship between these variants, the genes they impacted, and how they related 
to the phenotypes being studied were rarely immediately obvious [8].   
Even when GWAS lead variants fell within the boundaries of annotated genes, the possibility of 
long-range interactions made simple approaches including connecting the biological impact of tag 
GWAS SNPs to their nearest genes dubious. In a well-known example, a functional SNP 
associated with lactose intolerance (rs4988235) was found to reside within an intron of the 
minichromosome maintenance complex component 6 (MCM6) gene. Although it was known that 
expression of the lactase (LCT) gene was crucial for maintaining lactose tolerance, rs4988235 
was located 13.9 kilobases upstream of LCT [9]. Despite being in the intron of MCM6, 
subsequent molecular studies showed that rs4988235 was indeed capable of modulating LCT 
expression by disrupting a distal enhancer element that is active only in lactase-producing 
enterocytes [10]. Thus, although GWAS were highly effective at uncovering sets of candidate 
variants associated with common diseases, identifying the true subset of causal genetic variants, 
and understanding how these variants connected specific genes to disease phenotypes remained 
challenging, particularly for disease contexts where no clear connection could be made between 
gene function and disease pathology. 
Indeed, over 90% of disease-associated genetic variants identified through genome-wide 
association studies occupy noncoding regions of the genome [8]. These variants are broadly 
hypothesized to disrupt regulatory processes important for controlling normal biological functions, 
however interpreting their potential biological impact has remained challenging. In protein-coding 
DNA sequences, biological information is encoded in the form of codons that directly correspond 
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to amino acids. In contrast, noncoding regions of the genome can contain regulatory information 
that is often encoded as DNA sequence motifs. Making informed hypotheses on the mechanistic 
impact of genetic variation in noncoding DNA - in particular small insertions, deletions, or 
substitutions - is challenging both because much of the noncoding genome may not be functional, 
because many biological motifs are degenerate, and the specific mechanisms by which genetic 
variation impacts the activity of functional noncoding motifs are often unclear [11]. Thus, the 
promise of identifying specific biological mechanisms relating genetic variation to disease 
remained difficult for the vast majority of GWAS-uncovered SNPs. 
 
1.3: The challenge of interpreting noncoding variation 
Nevertheless, prior to the age of GWAS, traditional molecular biology approaches characterized 
numerous examples of noncoding genetic variants affecting DNA regulatory elements, including 
transcription factor binding sites [12], distal-acting transcriptional enhancers or silencers [13], and 
epigenetic regulatory marks that drive the pathogenesis disease [14]. Early studies of the 𝛽-globin 
gene were the first to demonstrate that genetic variants disrupting noncoding regulatory DNA 
could cause human disease [15]. It had been known previously that large deletions affecting the 
𝛽-globin gene produced thalassemias in patients. Unexpectedly, two patients were found to also 
manifest clinical and histological symptoms of classic 𝛽-thalassemia despite having a completely 
intact 𝛽-globin gene [16]. Restriction mapping revealed large deletions in these patients 
occupying noncoding DNase I hypersensitive sites far upstream of the 𝛽-globin gene. Further 
molecular studies elucidated that deletion of these DNase I hypersensitive sites led to loss of 𝛽-
globin expression, confirming a role for noncoding DNA in regulating gene expression, and also 
directly linking the disruption of noncoding regulatory DNA elements far upstream of encoded 
proteins to disease phenotypes [17].  
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The recognition that noncoding genetic variants could affect gene expression, sometimes over 
long ranges, provided one avenue for linking noncoding variants to their impact on genes, and 
ultimately genes to disease. The ability to capture global profiles of gene expression from 
biological samples through microarrays and high-throughput sequencing facilitated association 
studies between catalogued common genetic variants and changes in gene expression. Common 
variants found to be significantly associated with changes in gene expression, or expression 
quantitative trait loci (eQTLs) could now be mapped and identified for all 20,000 protein coding 
genes. The largest of these studies, the Genotype-Tissue Expression (GTEx) project, 
accumulated genotype, and gene expression profiles for thousands of individuals across 49 
tissues [18,19]. These eQTLs could provide a putative link between changes in noncoding DNA 
and the activity of specific genes, and generate new hypotheses linking genes and disease. 
Similar approaches were developed for other measurable quantitative molecular traits - including 
levels of alternative splicing, degrees of chromatin accessibility, DNA methylation, protein 
expression, and metabolites among others [20]. Although these approaches could associate 
noncoding genetic variants with molecular phenotypes in cells, ascertaining precisely how these 
variants could change biological mechanisms remained elusive. 
 
1.4: Untranslated regions in messenger RNA 
While there is growing appreciation for the impact of noncoding genetic variation in human 
disease, most previous work has focused on understanding the impact of this variation on 
regulatory elements in DNA; in contrast, genetic variants affecting RNA have received 
comparatively less focus. As genetic information in the genome is first transcribed from DNA to 
RNA, and then translated from RNA to protein, understanding how genetic variation impacts RNA 




The 5’ and 3’ untranslated regions (UTRs) are core components of all mature messenger RNAs 
(mRNAs) that contain regulatory elements controlling diverse post-transcriptional processes. 
Indeed, it has been observed in yeast that the majority of the variance in mRNA stability can be 
explained by cis-regulatory elements in UTRs and coding sequences [21]. Although these 
distinctions are not absolute, the 5’UTR is broadly thought to influence mRNA translation by 
modifying ribosome loading and the efficiency of translation initiation through structural elements 
such as hairpins [22], internal ribosome entry sites (IRES) [23], and sequences capable of 
initiating translation which include cognate or near-cognate start codons [24], and long repetitive 
trinucleotide repeats [25,26]. In contrast, regulatory elements in 3’UTRs - including secondary 
structure forming motifs and microRNA binding sites -are more broadly thought to modify post-
transcriptional mRNA stability, determine subcellular localization, and influence ribosomal 
recycling through interactions with the 5’UTR [27]. Moreover, sequence motifs in both 5’ and 3’ 
UTRs can serve as substrates for RNA binding proteins that greatly expand the repertoire of 
possible post-transcriptional RNA interactions impacting how and when mRNAs are translated or 
degraded. Thus, although genetic variants in both 5’ and 3’ UTRs have the capacity to affect 
protein expression through diverse mechanisms, dissecting which UTR variants can functionally 
impact biology from those that are silent remains challenging.  
Examples of genetic variants in UTRs causing disease have been identified by traditional linkage 
mapping approaches with experimental validations. Well-known functional elements within UTRs 
with disease relevance include 3’UTR polyadenylation signals [28], microRNA binding sites [29], 
and upstream open reading frames (uORFs) in 5’UTRs which modify translation [30]. Yet, broadly 
understanding how mutations in these elements can affect the biological processes which lead to 
pathology is difficult even when the functional impact of a mutation on a regulatory element is 
known. As an example, systematic mutagenesis of the canonical polyadenylation signal AAUAAA 
has elucidated the functional effects of all possible mutations on the motif’s function using 
synthetic 3’UTR constructs [31]. Yet, because 3’UTR regulatory elements are often repeated and 
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can act synergistically [32], the ultimate effect of mutations in one of several potential 
polyadenylation signals within a 3’UTR cannot be known without performing targeted biochemical 
studies. A consequence of the ambiguity inherent in interpreting noncoding genetic variation is 
that most known pathogenic variants are in the coding genome, even though many exome 
sequencing approaches can capture variation in UTRs. Because of this, expanding our capacity 
to interpret genetic variation in both 5’ and 3’ UTRs can have an immediate and direct impact in 
clinical applications and our understanding of disease biology. 
 
1.5: Identifying variants of interest in the noncoding genome 
The falling cost of sequencing has led to the creation of large databases of human genetic 
variation, facilitating new approaches to identify functional noncoding genetic variation. Under the 
principle that functional elements within the human genome tend to be less tolerant to genetic 
variation, identifying regions of the genome that are depleted of variation can help unmask 
functional regulatory elements in noncoding DNA. Many studies have analyzed allele frequencies 
to infer the action of natural selection on putative and predicted noncoding regulatory elements 
throughout the genome. Broadly, allele frequencies in an isolated population are shaped by three 
forces: mutation, drift, and selection. Genetic variants are introduced into the population through 
random mutation - a process that tends to introduce variation throughout the genome at a nearly 
constant rate [33]. Under the neutral theory of molecular evolution, most mutations have neutral 
or negligible effects on an organism's fitness and therefore will either be randomly removed from 
the population, or rarely, will become fixed in a population due to genetic drift [34]. Even more 
rarely, a mutation can be beneficial to an organism’s fitness, and selection may cause its allele 
frequency to increase within a population in a process known as positive selection. A hard sweep 
occurs when a beneficial mutation is introduced into a population by random mutation and rapidly 
reaches fixation [35]. Alternatively, positive selection may manifest as a soft sweep - when 
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changes in the environment make a previously neutral variant present within the population 
beneficial and its allele frequency increases [36].  
In contrast, when a mutation has deleterious effects on an organism’s fitness, negative, or 
purifying selection, tends to remove it from the population [33]. Thus allele frequencies for 
deleterious variants tend to remain low within a population, and by extension deleterious classes 
of mutations - such as protein truncating mutations, or mutations affecting essential splice sites - 
will exhibit enrichment in rare allele frequencies compared to classes of genetic variation that are 
selectively neutral [37]. This relationship between selection and allele frequencies can be used to 
explore hypotheses and identify new classes of functional genetic variation in the human 
genome.  
Prior to the generation of large databases of human genetic variation, putative noncoding 
regulatory elements were identified by comparing genome alignments from multiple species. 
Many early approaches relied on detecting non-neutral substitution rates over particular genome 
segments compared to expectation based on genetic drift [38]. Although effective at identifying 
long stretches of conserved sequences in the human genome, the power of these methods to 
detect non-neutral substitution rates at the individual nucleotides was limited by comparison, 
particularly at moderately conserved bases [38]. By comparing strongly conserved sequences 
across 29 different mammals, Lindblad-Toh and colleagues reported a map of human constrained 
elements which also appeared to be depleted of single-nucleotide polymorphisms in human data 
[39]. Thus, mutations affecting highly conserved noncoding DNA also appeared to be strongly 
depleted of variation in human populations [39]. The increasing availability of sequenced human 
genomes made it possible to implement approaches for inferring selection on specific genetic 
variants or groups of nucleotide positions in the human genome based on their allele frequency 
spectrum. Because functional regulatory elements in noncoding DNA are likely under a greater 
degree of selective constraint compared to neutrally evolving DNA segments, the site frequency 
9 
 
spectrum of variants with deleterious impacts on these functional elements are also expected to 
be enriched for rare allele frequencies.  
Studies inferring the importance of microRNA regulatory sites in humans were among the first to 
apply the relationship between selection and allele frequencies in human genomes. Using allele 
frequencies from the 1000 Genomes Project Chen et al. found that SNPs affecting 
computationally predicted conserved microRNA binding sites throughout the genome were 
enriched for rare allele frequencies compared to other conserved sequence motifs in 3’UTR 
sequences, suggesting that these sites were under a greater degree of negative selection [40]. 
By analyzing SNP density and the site frequency spectrum of genetic variants affecting ~22,000 
predicted microRNA binding sites conserved across 5 mammals, Chen and colleagues 
uncovered a significant depletion of genetic variation affecting these elements, suggesting that 
they were also more likely to be functionally important in 3’UTRs. Similar approaches have been 
used to examine patterns of selection on RNA-protein binding sites in RNAs [41], long-noncoding 
RNAs [42], and sites of m6A methylation in human mRNAs [43]. 
As the volume of sequencing data has increased, subsequent refinements have been made to 
this approach, most notably with the publication of the ExAC database in 2014 [37]. Here, Lek et 
al. developed a method to quantify the enrichment of rare allele frequencies for a given class of 
genetic variation using synonymous coding variants as a baseline for neutral selection, while 
adjusting for different rates of mutation based on local sequence context. This metric - termed the 
Mutability Adjusted Proportion of Singletons (MAPS) - has been applied to elucidate new classes 
of putatively functional genetic variation by identifying groups of variants under stronger negative 
selection compared to synonymous variants in coding regions of the genome. Indeed this 
approach has been applied to identifying deleterious classes of coding mutations [44], new 
putative splice-site disrupting mutations [45], and genetic variants creating new upstream open 
reading frames in mRNA 5’UTRs [46]. A key advantage of this approach is that biologically-
10 
 
informed hypotheses made about the potential functionality of a given class of genetic variants 
can be evaluated by analyzing their allele frequency spectrum in large population-scale 
databases.  
Here, we have applied metrics of negative selection across human cohorts to study noncoding 
regulatory elements in RNAs. To illuminate possible mechanistic relationships between genetic 
variation and gene regulation, we take a hypothesis-driven approach to assess the significance of 
specific classes of variation affecting both predicted and experimentally mapped RNA regulatory 
elements. We have additionally used a combination of public genotype and phenotype databases 
to explore the relevance of these variants to human disease. We have selected putative 
regulatory elements based on the availability of experimental data to support their existence 
across a large fraction of human mRNAs, and previously published literature supporting their 
potential functionality. The focus of this thesis is twofold: In Chapter 2, we investigate whether 
there is evidence for a functional role of G-quadruplex forming sequences in mRNA UTRs. In 
Chapter 3, we employ the same investigation framework to non-canonical open reading frames 
(ncORFs). Using public repositories of ribosome profiling to identify ncORFs, we elucidate 
selective pressures acting within these translated noncoding sequences and identify new patterns 
of functional variation in upstream open reading frames. For a subset of the variants we identified 
as functional and associated with disease, we performed luciferase assays to validate their effect 
on the translation of the downstream gene. Importantly, beyond the functional variants identified 
in this work, these studies represent a new approach to study and assess the impact of genetic 






CHAPTER 2: INTEGRATIVE ANALYSIS REVEALS RNA G-QUADRUPLEXES IN UTRS 
ARE SELECTIVELY CONSTRAINED AND ENRICHED FOR FUNCTIONAL 
ASSOCIATIONS * 
 
2.1: Secondary structures as RNA regulatory elements 
Unlike DNA, the single-stranded nature RNAs significantly expands the possibility for intrastrand 
base-pairing. RNA secondary structures have long been implicated in regulating gene expression 
through diverse post-transcriptional mechanisms. Strong secondary structures in 5’UTRs are 
known to repress translation of downstream coding sequences by blocking the formation of 
ribosome translation initiation complexes [22,47]. Specific 5’UTR secondary structures have also 
been observed to facilitate increased translation of downstream protein coding sequences 
through serving as internal ribosome entry sites (IRES) [23], or possibly through blocking 
translation initiation at inhibitory upstream open reading frames (uORFs) [22].  In contrast, 3’UTR 
secondary structures have been found to mask microRNA binding sites [47,48], facilitate 
interactions with RNA binding proteins [49,50], and regulate mRNA stability [51], or subcellular 
localization [52–54]. 
Several experimental approaches have been developed to map secondary structures 
transcriptome-wide [55–57]. These studies have generally uncovered an enrichment of secondary 
structures in both 5’ and 3’ UTRs compared to protein coding sequences where strong structure 
formation could disrupt translation elongation by ribosomes [58]. RNA secondary structures can 
also facilitate interactions with RNA binding proteins - either through helicases that unwind and 
 
*Published as Lee D.S.M. et al. Nat. Commun. 2020. [138] 
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resolve secondary structure elements in the 5’UTR to facilitate translation initiation, or through 
binding proteins which can mediate RNA subcellular localization [59]. 
 
 
2.2: G-quadruplexes are non-canonical secondary structures formed by nucleic acids 
Guanine rich nucleic acid sequences can form non-canonical secondary structures known as G-
quadruplexes (G4s) in both DNA and RNA [60]. In contrast to DNA G4s, RNA G4s are thought to 
form more readily in vitro due to their increased thermodynamic stability and reduced steric 
hindrance [61,62]. G4 secondary structures are formed through non-canonical base pairing of 
guanine side chains in G-rich sequences. The canonical G-quadruplex forming sequence 
consists of four trinucleotide G-runs separated by 1-7 nucleotides (Fig. 2.1).  
 
Figure 2.1: Canonical G-quadruplex motif. Schematic depicting a folded RNA parallel G-
quadruplex with the accompanying canonical G4 forming sequence. 
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Transcriptome-wide G4 mapping studies have uncovered evidence for widespread G4 formation 
in both 5’ and 3’UTR sequences [63,64]. In one approach, Kwok and colleagues developed a 
method to map transcriptome-wide G4 structures (rG4) by measuring reverse transcriptase 
stalling [63]. The method relies on isolating cellular mRNAs in vitro, while creating ionic conditions 
that are favorable to RNA G4 formation. These RNAs are then treated with reverse transcriptase 
(RT) to produce cDNA fragments which are isolated and subsequently sequenced. Because G4s 
will induce RT-stoppage due to steric blockage, evidence of significant RT stopping can be used 
to map secondary structures and identify G4 forming sequences within mRNAs transcriptome-
wide [63]. Results from these experiments uncovered specific enrichment of G4 structures in 5’ 
and 3’UTRs, and evidence that the capacity for G4 structure formation in mRNAs extends beyond 
the canonical G4 motif to include structures with extended loops, bulges in G-runs, and two 
quartets [63].  
Although G4 formation has been studied extensively in vitro, whether G4s in mRNAs exist in vivo 
has been an active area of debate. The single-stranded nature of RNAs is thought to favor G4 
formation due to reduced steric hindrance, however some in cellulo structural probing 
experiments using RT stopping have suggested that G4s typically exist unfolded at steady-state 
in most eukaryotic cells [65]. Guo et al. modified the RT-stopping approach to map RNA 
sequences capable of forming G-quadruplexes in vivo to probe for G4 formation in cellulo. 
Strikingly, they observed that while most predicted RNA G4-forming (pG4) sequences were 
unfolded at the steady-state, these same RNAs could form secondary structures when expressed 
in prokaryotes, suggesting that eukaryotic cells harbored factors capable of unwinding these RNA 
secondary structures [65].   
While specific RNA G4s have been associated with diverse biological functions, including 
mediating translational control [66,67], alternative splicing [68], subcellular localization [69], and 
RNA stability [70,71], the transcriptome-wide functional importance of UTR G4s has largely been 
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extrapolated from a limited number of experimental studies. To address this question, we 
combine several large-scale genomic and genetic data resources to assess evidence for 
evolutionary constraint on UTR pG4 sequences in humans, and enrichment for functional 
associations, including cis-eQTLs and protein binding sites. We show that UTR pG4 sequences 
are subjected to heightened selective pressures, have enrichment for cis-eQTL variants as 
identified by GTEx, and enrichment of RNA-protein binding interactions mapped by ENCODE. 
Taken together, our results support the biological significance of UTR pG4 sequences and 
highlight the importance of considering secondary structures in determining biological function in 
noncoding regions of the genome. 
 
2.3: pG4 exhibit heightened selective pressure within UTRs 
Putative G-quadruplex (pG4) forming sequences are enriched within untranslated regions of 
human messenger RNAs [63]. If these sequences are functional, they should exhibit patterns of 
genetic variation consistent with heightened evolutionary constraint. To test this hypothesis, we 
evaluated the distribution and frequency of single nucleotide variants occurring within UTR pG4 
sequences using whole-genome sequencing data from over 15,000 individuals from the public 
gnomAD release (version 2.2.1) [44]. We mapped pG4 sequences transcriptome-wide within 
annotated UTRs using the canonical G4 motif - GGG-{N-1:7}(3)-GGG (Fig. 2,1). Consistent with 
previous UTR G4 mapping efforts [72], we identified 2967 unique protein-coding genes encoding 
for at least one transcript isoform containing a pG4 sequence within the 5’UTR, and 2835 protein-
coding genes encoding a pG4 sequence within the 3’UTR. To further increase the specificity of 
pG4 sequences, we additionally defined a subset of experimentally supported rG4 sequences 
(466 in the 5’UTR, 1743 in the 3’UTR), consisting of canonical pG4 sequences with evidence of 
secondary structure formation as determined by biochemical structure mapping approaches [63]. 
Under the expectation that deleterious variation is continuously removed from the population, we 
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expect allele frequencies for variants affecting UTR pG4 sequences to be skewed towards more 
rare variation compared to non-pG4 UTR variants, reflecting their greater functional importance 
[40,73,74]. Because allele frequencies throughout the genome are affected both by local 
sequence context, which influences the mutability of a base at a given position, and nearby 
constrained functional elements that are under linked selection, we compared only single 
nucleotide variants affecting pG4 G-tracts to non-pG4 G-tracts (3 or more Gs) within UTRs 
belonging to a subset of transcripts whose estimated levels of overall constraint matched our 
UTR pG4-containing transcripts. This set of comparator transcripts was selected using the upper 
90% bound of the observed vs. expected (LOEUF) metric, as published by gnomAD [44]. This 
analysis revealed a significant depletion of variants in pG4 and rG4-seq G4s (Fig 2.2). For rG4 
sequences, we found mean allele frequencies were approximately one-third of that compared to 
non-pG4 G-tracts in constraint-matched transcripts in the 5’UTR, and 30% lower for the 3’UTR. 
For pG4 sequences without direct experimental support, G-tract variant frequency differences 
were similarly reduced (P<<2.2x10-16 for 5’UTR and 3’UTR; Fisher’s Exact Test). Taken together, 
this reduction in mean allele frequencies for variants in 5’ and 3’UTR pG4 sequences relative to 




Figure 2.2: Allele frequencies for G-run disrupting variants in gnomAD. Reduction in variant 
frequencies affecting guanine G-tracts within UTR pG4 forming sequences compared to matched 
non-pG4 G-tracts by transcript-level constraint. rG4-G-tracts are those within UTR pG4 that have 
evidence of secondary structure formation by rG4-seq. Asterisks denote P-value <<2.2x10-16 by 
Fisher’s exact test. 
To provide a complementary measure of sequence constraint, we assessed the number of 
polymorphic sites within UTR pG4 sequences compared to non-pG4 sequences. We applied a 
background model of neutral evolution to produce a distribution for the expected number of 
polymorphic sites in a given region of the genome under the assumption of neutral selection. This 
model has been shown to explain a median of 81% of the variability in nucleotide substitution 
probabilities for noncoding regions of the genome based on the local heptamer context of a given 
position [75]. Using this model, we partitioned UTR pG4 sequences into G-tracts and intervening 
gap sequences, and compared the ratio of observed versus expected polymorphic sites in the 
European sub-population of the 1000 Genomes Project. To additionally control for the possible 
confounding effects of linked selection driven by nearby constrained coding elements, or 
differences in sequencing depth across the 1000 Genomes Project, we produced an empirical 
distribution for observed vs. expected substitutions in constraint-matched 5’ and 3’UTR 
sequences. Consistent with the observed reduction in variant frequencies across UTR pG4s, we 
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find a significant reduction in the number of observed versus expected polymorphic sites within 
UTR pG4 sequences compared to non-pG4 forming regions of the UTR. Relative substitution 
rates in 5’ and 3’ UTR G-tracts are reduced approximately 30-40% compared to non-pG4 regions 
of constraint-matched UTRs (permuted P<10-4, for 5’ and 3’UTR pG4 and rG4) - Fig. 2.3. In 
contrast, gap sequences that are not predicted to be important for secondary structure formation 
in either 5’ or 3’ UTR pG4 contexts are not significantly different from the background UTR 
estimates, consistent with a pattern of selective pressure in 3’UTR pG4 sequences that primarily 
act to maintain the capacity for secondary structure formation across UTR pG4 sequences. 
 
 
Figure 2.3: pG4-forming G-tracts are depleted of polymorphic sites compared to 
intervening sequences. Reduction in the number of observed polymorphic sites compared to 
expectation in 5’ and 3’ UTR pG4 forming G-tracts using a nucleotide substitution model based 
on local sequence context (permuted P < 1x10-4  in all G-tracts compared to matched non-pG4 
UTR sequences). Error bars represent bootstrapped 90% confidence intervals for the ratio of 
observed vs. expected substitutions within each pG4 region. Red line and shaded regions 
represent the observed vs. expected number of substitutions in non-pG4 UTR sequences 
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matched by transcript-level constraint and 90% confidence intervals, respectively. Gray-dashed 
line represents an expected vs. observed ratio of 1:1. 
The reduction in allele frequencies, and in the number of polymorphic sites within UTR pG4 
sequences, indicate UTR pG4 are under heightened selective pressures compared to non-pG4 
UTR regions. To place the degree of selection on UTR pG4s in context, we applied a mutability-
adjusted proportion of singletons (MAPS) metric, which measures the relative enrichment for rare 
variation within a particular class of variants accounting for differences in mutation rates based on 
local sequence context [37]. A similar approach has been recently used to assess the degree of 
selective pressure against upstream open-reading frame-creating variation within 5’UTR variants 
in the gnomAD database [46]. Within the canonical pG4 motif, we predicted that variants affecting 
the central guanine of each G-tract should be most constrained, since biophysical studies of G4 
stability have shown that mutations affecting the central tetrad (2nd guanine of each trinucleotide 
guanine repeat) are most detrimental to secondary structure stability [76]. To remove the 
ambiguity of which specific guanines are involved in secondary structure formation when more 
than three guanines form a pG4 G-tract, we focused only on single nucleotide variants within 
trinucleotide G-tracts (n = 3137). By examining variation across each pG4 G-tract, we found 
central guanine positions within UTR pG4 G-tracts are consistently enriched for singletons (one 
sequenced variant in gnomAD whole genomes) compared to non-pG4 UTR variants (Fig. 2.4, 
permuted P<10-4). Notably, non-pG4 UTR variants reflected a similar degree of constraint as 
synonymous coding variants, while central position guanines exhibit a similar degree of selective 
pressure as missense variation in protein-coding regions of the genome. Interestingly, the most 
proximal and distal 5’ and 3’ guanine of each trinucleotide pG4 G-tract demonstrated significantly 
less enrichment of singleton variants within gnomAD across gene classes compared to central 
guanine positions as determined by permutation testing (P-values = 0.0237 and 0.0022 
respectively - Figure 2.15). This result suggests these positions are under less negative selection 
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compared to central positions, perhaps because mutations in these positions can preserve the 
potential for RNA to form non-canonical G4 2-quartets [63]. 
 
Figure 2.4: Mutability-adjusted proportion of singletons (MAPS) for each set of variants 
affecting trinucleotide guanines within the meta-pG4 sequence motif. Central position 
guanines consistently demonstrate the highest MAPS scores (are most constrained) compared to 
non-pG4 UTR variants (permuted P < 1 × 10−4) across all contexts. Error bars represent the 5% 
and 95% bootstrap permutations for each variant class. Purple-dashed line, orange dashed line, 
and gray-dashed line represent MAPS score for Ensembl predicted high-impact coding (predicted 
loss-of-function), missense, and synonymous mutations respectively. 
Finally, to provide additional control for our sequence context-derived mutability rates, we 
compared the MAPS metric for UTR pG4 G-tracts to UTR trinucleotide G- and C-runs not 
involved in pG4 formation. Although these non-pG4 G- and C-tracts exhibit modest enrichment 
for rare variation at the central position, there is a significantly greater enrichment in singletons at 
the central position of the UTR pG4 G-tract compared to non-pG4-forming contexts (Figure 2.15 - 
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permuted P=0.0195). Thus, the excess rare variation is specific to the guanine within pG4 G-
tracts most important for maintaining G4 secondary structure. 
 
2.4: Most pG4 motifs in UTRs are isoform-restricted 
Many functional UTR elements, including upstream open reading frames (uORFs), AU-rich 
elements, and microRNA binding sites are frequently included in alternative 5’ or 3’ UTR isoforms 
of the same gene [77,78]. Alternative UTR inclusion is hypothesized to significantly diversify the 
number of possible post-transcriptional regulatory interactions for a given gene [79]. Given the 
observed constraint over UTR pG4 sequences, we hypothesized that UTR pG4 sequences 
should also exhibit patterns of alternative inclusion or exclusion. 
To evaluate the extent of alternative UTR pG4 inclusion, we mapped UTR pG4s to protein-coding 
transcripts for each gene in the Ensembl transcriptome database. Genes were considered to 
produce constitutive UTR pG4 sequences when all annotated protein-coding transcript isoforms 
contained at least one pG4, or alternative UTR pG4 sequences if at least one transcript isoform 
lacked the pG4 sequence. Most constitutive pG4 genes were found to express UTRs with 
identical pG4s across all transcript isoforms, however 36 of 620 5’UTR and 75 of 1275 3’UTR 
constitutive pG4 genes produced transcript isoforms with non-identical pG4 sequences. For this 
subset of non-identical pG4 transcript isoforms, approximately one-third differ by the addition / 
subtraction of pG4 motifs (13/36 for 5’UTR, 20/75 for 3’UTR). Strikingly, we found that over half of 
all genes producing UTR pG4 transcripts also encoded for alternative UTRs lacking pG4 motifs 




Figure 2.5: Distribution of 5’ and 3’ UTR transcript isoforms with constitutive or non-
constitutive pG4 sequence motifs. (a) Most genes with mRNA transcripts with UTR pG4 
sequences also produce alternative isoforms lacking UTR pG4s (non-constitutive). (b) 
Overrepresented biological processes for protein-coding genes producing both pG4 and non-pG4 
5′ or 3′ UTR isoforms (n = 3148). GO-term enrichment was performed using PantherDB55 and 
enrichment was determined by meeting a Benjamini–Hochberg adjusted P value cutoff of 0.05 by 
Fisher’s exact test.  
Indeed, of the 5235 total UTR pG4-containing genes, 3395 exhibited either alternative 5’ or 3’ 
UTR pG4 inclusion, and 284 produced UTRs with both alternative 5’ and 3’ pG4s. This 
distribution of alternative and constitutive pG4 genes for each UTR context was found to be highly 
significant through permutation testing (P-value<0.0001 for 5’ and 3’ UTRs). Moreover, MAPS 
scores for alternative UTR pG4 indicate that their second guanine position is under a similar 
degree of constraint as for all UTR pG4 and is comparable to that of missense variations for the 
set of alternative pG4s found in genes with any disease association in ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/) (Fig. 2.4). As is the case for all UTR pG4, this second 
guanine position was significantly more enriched for rare variation compared to either the 5’ or 3’ 
guanine (permuted P-value = 0.0138 and 0.004 respectively). Constitutive UTR pG4 sequences, 
in contrast, do not show a similar pattern of selective constraint acting on the second G-tract 
guanine, possibly because these sequences tend to be under less stringent selective pressures, 
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or because we are underpowered to detect significant enrichment in rare variation. Notably the 
MAPS metric for the central G-position of alternative pG4 sequence G-tracts remained 
significantly higher than matched, non-pG4 G-tracts (permuted P=0.0124 - see Figure 2.15 for 
comparison of constitutive pG4 G-tracts and other pG4 gene sets). 
We next asked whether the expression of alternative pG4 isoforms tend to be restricted or shared 
across different tissue contexts. Using transcript-isoform expression data across 45 different 
tissues from GTEx, we find that many tissues appear to express both pG4 and non-pG4 
transcripts simultaneously (Fig. 2.6). Notably, this simultaneous expression of both pG4 and non-
pG4 isoforms also occurs in single-cell contexts (lymphocytes, fibroblasts), demonstrating that 
this effect is not due to cellular heterogeneity in bulk tissue samples. Thus, most UTR pG4-
encoding genes express alternative isoforms which lack pG4 sequences, and that the 
simultaneous expression of both pG4-isoforms and non-pG4 isoforms is widespread across 
multiple tissue and cellular contexts. 
To explore the functional associations of alternative UTR pG4 genes we performed a gene 
ontology analysis. We find that these genes are frequently involved in dynamic intracellular 
processes, including signal transduction, cellular responses to stress, and metabolic regulation 
(Fig. 2.5b). In contrast, constitutive pG4 genes showed enrichment for biological processes 
associated with the activation of gene expression in discrete temporal stages, including those 
involved in tissue development, pattern specification, and cellular differentiation. These 
observations, coupled with our finding that many tissues simultaneously express both pG4 and 
non-pG4 isoforms of the same gene, suggests that isoform-switching between pG4-containing or 
non-pG4 transcripts may facilitate dynamic cellular responses to external stimuli. More broadly, 
our results demonstrate considerable variation in alternative pG4 inclusion within UTRs across 
multiple tissue contexts, and suggest that the relative abundance of pG4 and non-pG4 UTRs may 




Figure 2.6: Median expression (TPM) of each pG4-transcript or non-pG4 transcript was 
assessed for each tissue context. For the subset of genes producing UTRs with alternative 
pG4 inclusion, both pG4-containing and non-pG4 isoforms are frequently expressed 
simultaneously. Transcripts were considered as expressed if their median TPM measurement 
exceeded one TPM for each tissue context considered. The proportion of pG4 genes expressing 




2.5: pG4 motifs in the 5’ and 3’ UTR are enriched for cis-eQTLs 
We next evaluated the potential regulatory consequences associated with mutations affecting 
UTR pG4s, hypothesizing that variants affecting pG4 sequences might also be more likely to be 
associated with changes in gene expression. To test this hypothesis, we compared the proportion 
of annotated cis-eQTLs versus non-eQTL SNPs identified by GTEx across pG4 and non-pG4 
regions of the UTR, finding significant enrichment for either nominally significant or lead eQTL 
variants (lowest P-value variant) in 5’ and 3’ UTR pG4 sequences compared to non-pG4 regions 
of UTRs (Fig. 2.7). Notably, we continue to observe an enrichment of cis-eQTL variants in UTR 
pG4 sequences using a reduced set of putatively causal cis-eQTLs [80], suggesting that 
disruption of UTR pG4 sequences may cause changes in post-transcriptional regulation.  
We next explored the direction of gene expression changes for UTR pG4 cis-eQTLs, considering 
all variant-tissue effects separately for each significant variant-tissue interaction. We 
hypothesized that variants affecting pG4 G-tracts are more likely to disrupt the structural integrity 
of the RNA G4s, and thus might influence gene expression differently than variants affecting gap 
(non-G-tract) sequences within pG4 motifs. Since the magnitude of normalized effect-size 
estimates in GTEx has no direct biological interpretation, we compared differences in the 
direction of variant effects across pG4 and non-pG4 sequences. As expected, UTR variants in 
non-pG4 regions are not significantly biased towards increasing or decreasing gene expression, 
regardless of whether the mutation affected a G-tract, or non-pG4 G-tract nucleotide. In contrast, 
mutations affecting structurally important pG4 G-tracts in the 3’UTR tend to increase mRNA 
expression compared to non-G-tract bases (OR 1.75, 95% CI: 1.34 to 2.30, P<3.0-5) - Fig. 2.8. 
This relationship for the 5’UTR was not observed. Given the role of the 3’UTR in mediating mRNA 
stability, the tendency for G-tract base mutations to increase gene expression suggests the 





Figure 2.7: Analysis of frequency of variants in UTR pG4 also being GTEx cis-eQTLs 
compared to non-pG4 UTR variants. GTEx cis-eQTLs are enriched within UTR pG4 relative to 
the number of tested (non-eQTL) SNPs when comparing lead SNPs, high-confidence causal, 
nominally significant, and nominally significant in RBP-binding sites in matched UTR regions. 
Error bars represent the 95% confidence interval for the odds ratio.  
 
Figure 2.8: Annotated cis-eQTLs affecting 3’UTR pG4 sequences tend to increase gene 
expression. Odds ratio for a cis-eQTL increasing gene expression across all cis-eQTL-tissue 
effects (n = 379,441, P value < 2e−16, Fisher’s exact test), where the variant affects a pG4 G-tract 
compared to those affecting gap sequences. Error bars represent the 95% confidence interval for 
the odds ratio.   
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2.6: RNA-protein binding sites are enriched over UTR pG4 regions 
Transcriptome-wide RNA structure mapping studies have suggested that most RNA G4 are 
unfolded in eukaryotes, but not in prokaryotes, leading to the hypothesis that intracellular factors 
bind RNA G4s to maintain their unfolded state in cellulo [65]. To gain insights into regulatory 
mechanisms mediating pG4 effects on gene expression we investigated the propensity of protein-
binding sites to overlap UTR pG4s by comparing the proportion of UTR pG4 sequences 
overlapped by RNA-binding protein (RBP) binding sites published by ENCODE to non-pG4 
forming regions of the UTR[81]. This data consists of cross-linking immunoprecipitation 
sequencing (CLIP-seq) peaks, called from K562 or HepG2 cell lines for over 150 RBPs, 
containing at least one highly reproducible (IDR = 1000) [82] binding peak within the 5’ or 3’ UTR. 
When compared to non-pG4 regions of the UTR, the frequency of overlap between unique (non-
overlapping) RBP binding sites and pG4 sequences was almost 6-fold (P<<2.2x10-16, Chi-
square test) higher compared to non-pG4 sequences in the 5’UTR (Fig. 2.9). Enrichment of RBP 
binding locations over pG4 sequences within the 3’UTR was markedly higher (14-fold, 
P<<2.2x10-16, Chi-square test). Given the enrichment within UTR pG4s for cis-eQTLs and 
protein binding sites, we tested for significant colocalization between these two features in pG4s. 
Taking the subset of pG4 regions overlapped by any protein binding sites, we examined the 
density of cis-eQTLs in UTR pG4 regions also overlapping CLIP-seq peaks. When all nominally 
significant cis-eQTLs are considered, we observe a significant enrichment of cis-eQTLs in the 
3’UTR that are also protein binding sites (Fig. 2.7), indicating that variation in 3’UTR pG4 
sequences may influence gene expression through changing RNA-protein interactions.  
Given the observed association between protein binding sites and pG4 sequences, we next 
asked whether specific proteins’ binding sites are enriched for pG4s. For each protein, we 
determined the proportion of protein-specific binding sites containing pG4 sequences, against the 
total background rate of all CLIP-seq binding sites containing pG4 sequences. To determine a 
significant overrepresentation of pG4 sequences within a given protein’s binding sites, we 
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performed a hypergeometric test against the null hypothesis that there is no overrepresentation of 
pG4 binding sites within the set of a protein’s binding sites - Fig. 2.9. 
 
 
Figure 2.9: Density of RBP-binding sites per kilobase of pG4 sequence compared to non-
pG4 regions of the UTR.  pG4 sequences are more frequently overlapped by RBP binding sites 
compared to non-pG4 sequences within the UTR (P value ≪ 2.2 × 10−16, chi-square test). 
This analysis revealed enrichment for proteins that have been implicated in RNA G4 binding 
(GRSF1, FUS), and those that, to our knowledge, have not previously been associated with RNA 
G4 structures (PRPF4, GTF2F1, and CSTF2T). GRSF1 is a cytoplasmic protein involved in viral 
mRNA translation and has recently been shown to play a role in the degradation of G4-containing 
RNAs in mitochondria [83,84]. Other proteins with significant enrichment for pG4 binding include 
those involved in mitochondrial processes (FASTKD2), transcriptional activation (GTF2F1), 
mRNA transport (FAM120A), mRNA degradation (XRN2, UPF1), in addition to several proteins 
implicated in RNA polyadenylation and splicing (CSTF2T, PRPF4, RBFOX2), and surprisingly, 
micro-RNA (miRNA) biogenesis (DCGR8, DROSHA). Interestingly proteins demonstrating a 
preference for binding UTR pG4 sequences tend to bind both 5’ and 3’ UTR contexts, with 14 out 
of 20 proteins’ binding peaks showing enrichment for overlap over 5’ and 3’ pG4 sequences in 
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HepG2, and 17 out of 25 for K562 independently. Taken together, these data suggest that RBP 
binding is enriched in UTRs over pG4 sequences, and that RBP-pG4 interactions may regulate 
gene expression.  
An analysis of gene expression changes with sh-RNA knockdown for the majority of pG4-
enriched binding proteins showed genes containing pG4 in either the 5’ or 3’ UTR are much more 
likely to be significantly differentially expressed compared to non-pG4 genes (Figure 2.16). 
Approximately one-third of the proteins exhibiting a binding preference for UTR pG4 change the 
expression of pG4-containing genes concordantly across K562 and HepG2 cells (GTF2F1, 
FASTKD2, UPF1, NONO, GRSF1, NCBP2, AKAP8L, DDX6, FKBP4, TAF15, LARP4). Of these 
11 RNA-binding proteins, knockdown of eight tends to decrease expression of UTR pG4 genes 
(GTF2F1, UPF1, NONO, GRSF1, NCBP2, AKAP8L, DDX6, LARP4), while knockdown of three 
(FASTKD2, FKBP4, TAF15) tends to increase their expression, suggesting that most of the 
proteins enriched for pG4 binding tend to increase, or stabilize RNA expression rather than 
facilitate their degradation. This result is consistent with our finding that cis-eQTLs affecting 
3’UTR pG4 sequences are more frequently associated with decreasing gene expression.  
Finally, to explore the potential existence of post-transcriptional regulatory networks relying on 
shared RNA G4-protein interactions, we tested for a significant overlap in pG4 containing 
transcripts targeted by each protein enriched for pG4 binding interactions. Taking the set of 31 
proteins with significant overrepresentation for pG4 binding (Bonferroni-corrected P<0.001) and 
at least 20 unique pG4 binding sites in HepG2 or K562, we assessed overlaps between the 
various proteins’ pG4 gene targets (Fig. 2.10). We found low overlap of targets in helicases that 
have been hypothesized to bind RNA G4s frequently, such as DDX6, DDX51, and DDX52. In 
contrast, we find a subset of G4-binding proteins sharing a significant degree of overlap in G4-
gene targets, including FASTKD2, FAM120A, CSTF2T, PRPF4 and GTF2F1, none of which have 
been shown to bind RNA G4 structures previously. These data point to possible mechanisms of 
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gene control relying on the shared interactions of these proteins with their respective RNA 
targets. Indeed, assessing the functional associations of 133 pG4 genes sharing at least 3 out of 
5 protein-binding interactions from this module revealed enrichment for genes involved in viral 
process (GO:0016032, FDR-adjusted P=0.0268), suggesting that these genes and putative pG4 
binding proteins, may be involved in mediating host-viral interactions within the cell. 
 
Figure 2.10: Enrichment of specific protein–pG4 binding sites using CLIP-seq data from 
ENCODE. a, b Enrichment of specific proteins over pG4-binding sites within the 5′ UTR (left) and 
3′ UTR (right)—red line corresponds to P = 0.0001 (hypergeometric test). c, d Heatmaps depicting 
the significance of overlap (hypergeometric −log P value) in pG4 gene targets for proteins found 
to bind pG4 sequences preferentially. 
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2.7: 3’UTR pG4 in disease-causing genes are enriched for variants 
Multiple studies assessing evolutionary constraints in protein-coding regions of the human 
genome have shown that regions depleted of genetic variation are also enriched for pathogenic 
variation [85–87]. Under the principle that purifying selection removes deleterious variants from 
the genome to produce regions depleted of genetic variation, we expect UTR pG4s should also 
be enriched for pathogenic variation. Since pathogenic variants in ClinVar are overwhelmingly 
annotated in protein-coding regions of the genome, we are underpowered to test for a direct 
association between the set of annotated pathogenic variants and UTR pG4 sequences. Instead, 
we asked whether potentially pathogenic variation in ClinVar is enriched within UTR pG4 
sequences in known disease-associated genes. To test this hypothesis, we mapped all single 
nucleotide variants annotated in the most recent release of the ClinVar database available at the 
time of this writing [88] (April, 2019) across UTRs, and compared their relative density in pG4 
versus non-pG4 sequences in disease-associated genes. We defined the set of disease-
associated genes as any gene with at least one variant having an annotated as Pathogenic or 
Likely Pathogenic in ClinVar, excluding variants with an annotation of Benign or Likely_benign. To 
maximize our power for this analysis, we expanded our set of rG4-seq G4s to include all non-
canonical G4-forming sequences mapped and reported by rG4-seq in HeLa cells [63]. We found 
modest enrichment for variation in 3’UTR pG4 sequences, rG4 3’UTR sequences, and a notable 
enrichment in 3’UTR pG4 sequences within annotated RBP binding sites from ENCODE in 
disease-associated genes compared to non-pG4 forming regions of the 3’UTR - Fig. 2.11a (All 
pG4: OR 1.51, 95% CI 1.20-1.88, P<0.0005, rG4-seq pG4: OR 1.18, 95% CI 0.98-1.42, P=0.067, 
RBP pG4: OR 6.01, 95% CI 3.87-8.91, P<5e-12 - Fisher’s Exact Test). In contrast, there was only 
evidence for enrichment of variants in the 5’UTR rG4 sites (OR 2.32,  95% CI 1.93-2.78, 
P<2.25x10-16 Fisher’s Exact Test), but not pG4 or pG4-RBP overlap regions. It is important to 
note though that the above statistical test only contrasts relative enrichment of putative 
pathogenic variants in pG4 vs. non pG4 UTR sequences. Thus, the lack of such relative 
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enrichment in the 5’ UTR may reflect the generally greater density of other functional elements 
within 5’UTR sequences. In conclusion, these data imply that disease-associated noncoding 
variation may be enriched in 3’UTR pG4 regions. 
Finally, we tested for enrichment of common variants that have been associated with disease 
phenotypes using annotations available in the NIH GWAS Catalog (April 2019). There were not 
enough GWAS-associated lead variants within UTR pG4 regions to detect enrichment (7 variants 
in 5’UTR pG4, 4 in the 3’UTR pG4). However, given the enrichment for cis-eQTLs in UTR pG4, 
we hypothesized that disruption of UTR pG4 sequences could affect post-transcriptional 
mechanisms regulating gene expression, thus providing a potential mechanistic link between 
GWAS variants and their observed phenotypes. To test this hypothesis, we assessed evidence of 
allelic imbalance at select GWAS SNPs either falling within a UTR pG4 region, or in high LD with 
a common SNP (r-squared > 0.85 in the GBR population of 1KG) falling within a UTR pG4 in 
GTEx. Despite being limited by the number of heterozygous individuals in GTEx with matched 
whole-genome sequencing available, our analysis uncovered several proxy SNPs in high LD with 
GWAS tag-SNPs (Figure 2.18), and one GWAS lead variant exhibiting evidence of significant 
allelic imbalance. The lead GWAS variant, rs1048238 is a common SNP within the 3’UTR of 
HSPB7, a chaperone protein that is highly expressed in heart and skeletal muscle and has been 
associated with hypertension in a recent GWAS [89,90] (Fig. 2.11b). We found that rs1048238 
exhibited a substantial imbalance of reads mapping to the alternative allele in 84 heterozygous 
individuals, even after correcting for read-mapping biases using WASP-filtering [91]. Taken 
together, these results demonstrate that the predicted pG4-disrupting variant is associated with 
increased expression of the alternative allele at this locus (Fig. 2.11c-d). This association is 
consistent with our previous observations from transcriptome-wide mapping of pG4 eQTL 
showing that 3’UTR pG4 eQTLs tend to increase gene expression (Fig. 2.9) and suggest that the 






Figure 2.11: UTR pG4 sequences are enriched for known pathogenic, and putative 
disease-associated genetic variants. (a) Annotated variants within ClinVar disease-associated 
genes occur with greater frequency in UTR pG4 sequences compared to non-pG4 UTR regions 
in the 3′ UTR across multiple G4 subsets (error bars represent the 95% confidence interval). (b) 
rs108348 maps to a 3′ UTR pG4 G-tract guanine within the primary HSPB7 transcript, which is 
encoded on the negative DNA strand. The SNP disrupts the canonical G4 sequence motif by 
causing a G to A mutation in the RNA transcript. (c, d) WASP-mapping of allele-specific reads in 
84 GTEx skeletal muscle samples reveals significant allelic imbalance favoring expression of the 
alternative allele (P value < 1 x 10−100, likelihood ratio test). Boxplot in c represents median and 1.5 
times the interquartile range of WASP-aligned RNA-seq reads aligning to the ference (red) or 
alternative (blue) allele. 
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2.8: Summary and future directions 
We have applied a deep catalog of human genetic variation to assess evolutionary pressures 
over putative G-quadruplex forming sequences within 5’ and 3’ UTRs. We hypothesized that if 
these regions are functionally important they should be depleted of variation. Supporting this 
hypothesis, we show that variation within UTR pG4 sequences is reduced compared to non-pG4 
UTR regions using a local sequence context based substitution model. Moreover, our analysis of 
positional constraint within the meta-pG4 motif reveals selective pressures acting on central 
guanines of each trinucleotide G-tract comparable to that of missense mutations in protein-coding 
regions of the genome. These findings are consistent with in vitro biophysical studies of DNA G-
quadruplex stability, which have shown that central position substitutions are most destabilizing, 
and consequently were predicted to be the most deleterious for native biological functions of G4s 
[76,92,93]. Interestingly, we find that non-central guanines appear less constrained compared to 
central positions - possibly because mutations at these positions may preserve the potential for 
RNA to form non-canonical G4 2-quartets. Indeed, these G4 2-quartets have been estimated to 
account for 1/4 to 2/3 of all RNA G4 structures observed by transcriptome-wide rG4-seq in HeLa 
cells [63].  
We also uncover a greater proportion of cis-eQTLs mapping to pG4 regions compared to non-
pG4 sequences within both 5’ and 3’ UTRs. Our analysis of nominally-significant cis-eQTL 
enrichment in UTR pG4 sequences may be confounded by the presence of linked SNPs that 
reach nominal significance because of their proximity to causal eQTL SNPs, however this likely 
deflates our estimates of enrichment in UTR pG4 sequences because the relatively smaller size 
of pG4 motifs (15 - 33nt) makes multiple linked nominally significant cis-eQTLs more likely to 
occur along the length of non-pG4 UTR regions. Nevertheless, the enrichment of cis-eQTLs 
within UTR pG4 remain unchanged when we limit each UTR pG4 feature to contain at most 1 




Using CLIP-seq data for over 150 proteins published by ENCODE, we find 15 proteins whose 
binding sites are enriched for pG4 sequences across two cell lines, and identify regulatory 
modules associating a set of RNA binding proteins, including FAM120A, FASTKD2, and CSTF2T, 
with pG4 gene targets involved in viral mRNA expression. Indeed, several examples of viral hi-
jacking of eukaryotic RBPs have been reported in the literature [94,95], and G4-forming 
sequences have been found to occur commonly in multiple viral genomes [96]. This, coupled with 
the observation that RNA G4s appear to be universally depleted within prokaryotic transcriptomes 
[65], suggests that viruses might rely on G4s as a mechanism for co-opting host cell machinery 
involved in gene expression and RNA regulation. 
There are three primary limitations to the current study. First, we applied a text-based approach 
towards identifying regions of putative G-quadruplex formation within RNA UTRs. Although this 
approach has been commonly employed in previous work [63,72], there exists a considerable 
literature regarding possible variations to the canonical G-quadruplex forming sequence and 
methods that capture more variable motif definitions [97,98]; [99]. Given the comparably limited 
evidence that many of these alternative G-quadruplex sequences form readily in cellulo we used 
a more stringent motif definition, but alternative G4 sequences will have been missed in our 
analysis. The modest enrichment in singletons at the central position of trinucleotide G- and C-
tracts not matching our canonical pG4 sequence motif is consistent with this possibility. Thus, our 
assessment of sequence constraint and functional enrichment within UTR G4 forming regions is 
likely incomplete. Secondly, although we have uncovered evidence suggesting G4 secondary 
structure formation is constrained, whether these pG4s form secondary structures in vivo remains 
unclear. Finally, our assessment of selective pressures acting across UTR pG4 sequences using 
the MAPS metric is limited in power by low variant numbers. Nevertheless, we report multiple 
lines of evidence supporting the biological importance of putative secondary structure-forming G-
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quadruplexes within UTRs. Although RNA UTRs represent only a small fraction of the noncoding 
genome, they are core components involved in mediating post-transcriptional regulation of gene 
expression. Ultimately, we hope this work will motivate researchers to consider G4s and other 




2.9: Supplementary Materials to Integrative analysis reveals RNA G-Quadruplexes are 
selectively constrained and enriched for functional associations 
 
 
Figure 2.12: Distribution of binned distances for mapped canonical 5’ (left) and 3’ (right) 
UTR pG4 sequences with respect to protein-coding sequences across pG4-UTR 
containing mRNA transcripts. The relative locations of pG4 sequences within UTRs are plotted 
(x-axis), with 0 being adjacent to the coding sequence, and 1 representing the full-length of the 





Figure 2.13: Quantile-quantile plot showing matching between pG4 and non-pG4 
containing transcripts based on  LOEUF scores for 5’UTR (left) and 3’UTR (right) 
transcripts. Allele frequencies (Figure 1b) and substitutions (Figure 1c) were compared across 
constraint-matched transcripts using gnomAD’s LOEUF metric to control for the possibility that 
nearby constrained coding sequences might affect local allele frequency estimates. LOEUF 
scores for non-G4 transcripts plotted on the X-axis and LOUEF scores for G4-containing 





Figure 2.14: The empirical distribution of observed vs. expected number of substitutions 
across 10,000 bootstrapped 5’ and 3’ UTR regions in the European subpopulation of the 
1000 Genomes Project Phase 1 release. Red dotted line indicates the observed vs. expected 
ratios estimated by applying the noncoding heptamer mutation model across 5’UTR and 3’UTR 









Figure 2.15: MAPS scores for All (black), G4 (red), and non-G4 GGG/CCC (blue) variants 
across multiple gene sets. Error bars represent 90% CI from 10,000 bootstraps.Top ⅓ LOEUF 
represent MAPS scores for pG4 versus non-pG4 variants within the top-1/3rd most constrained 
genes as estimated by the gnomAD LOEUF metric. Alt. pG4 represent alternatively included pG4 
sequences while Const. pG4 represent constitutively included pG4 sequences. ClinVar pG4 
sequences are those pG4 within UTRs of disease-associated genes in ClinVar. Permutation P-
values for the second guanine of each trinucleotide G-tract context compared to non-pG4 G-
tracts in UTRs are: P=0.0195 for all UTRs, P=0.1063 for Top ⅓ LOEUF, P=0.0124 for Alt. pG4, 
P=0.4653 for Const. pG4, and P=0.0579 for ClinVar pG4. Genome-wide MAPS scores for 
synonymous (grey), missense (orange), and putative loss of function (red) protein-coding 




Figure 2.16: Distribution of odds ratio with error bars representing 95% confidence interval 
for changing gene expression of a pG4 containing gene versus a non-pG4 containing gene 
with sh-RBP knockdown in ENCODE as determined by Fisher’s Exact Test.  Results for 
HepG2 (a) and K562 (b) are shown. Colors represent a tendency for an RBP-knockdown to 
increase the expression of pG4 containing genes (blue), decrease their expression (red) or have 
no effect on changing the expression of pG4 genes (grey) at an FDR < 0.001. Proteins having the 
same direction on changing pG4 gene expression across both HpeG2 and K562 cell lines are 




Figure 2.17: Boxplot of distribution of distances between 5’ UTR (a) and 3’UTR (b) pG4 
sequences and nearest annotated protein-coding exons in ClinVar disease-associated 
genes showing the 1.5 times the interquartile range and median values. Compared to 
randomly selected positions within non-pG4 5’ and 3’ UTRs of ClinVar disease-associated genes, 




Figure 2.18: Additional common SNPs in high LD (r2 > 0.85 in the 1000 Genomes GBR 
population) with GWAS tag SNPs exhibiting evidence of allelic imbalance in UTR pG4 
sequences. rs352047, rs77247684, and rs761153 affect 3’UTR pG4 sequences. rs11864750 
affects a 5’UTR pG4 sequence.  
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CHAPTER 3: DISRUPTING UPSTREAM TRANSLATION IS ASSOCIATED WITH 
LOSS-OF-FUNCTION IN HUMAN DISEASE* 
 
3.1: Ribosome profiling and non-canonical open reading frames 
With the completion of the human draft genome sequence, elucidating the number of protein-
coding genes represented a major challenge. While searching for known homologs using existing 
gene databases could help map the locations of known protein-coding sequences in the human 
genome, these strategies depended on the completeness of existing databases and the degree 
of evolutionary relatedness between humans and other species [100]. Naive approaches to 
mapping protein coding sequences relied on identifying sequence stretches that could 
correspond to open reading frames (ORFs) based on the amino acid code. These techniques 
identified sequence stretches consisting of first identifying an upstream start codon, and scanning 
along the DNA sequence in search for an in-frame downstream TGA, TAG, or TAA stop codon. 
Under the assumption that the DNA has a random sequence, and ~50% GC-content, a 
trinucleotide stop sequence is expected to appear once every 64 base pairs. Putative protein-
coding ORFs could therefore be identified if they extended significantly beyond this expected 
length. Crucially, ORFs smaller than 64 base pairs could not be distinguished from background 
nucleotide distributions and therefore could not be annotated as functional with certainty. While 
this ORF-scanning approach could be used to identify almost all the known protein-coding genes 
in prokaryotes, the increased size and widespread presence of introns of the eukaryotic genome 
presented significant challenges. 
 
*Published as Lee, D.S.M. et al. BioRxiv 2020. https://doi.org/10.1101/2020.09.09.287912. 
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To address these challenges, several refinements to the basic ORF-scanning approach were 
proposed. These included using biased codon distributions of known protein-coding regions of 
the genome to assess new putative ORFs, identifying exon-intron boundaries using known splice-
site motifs, and matching putative genes to upstream regulatory sequences including CpG islands 
that typically mark the beginning of protein-coding genes [100]. Although these strategies 
significantly improved computational ORF mapping from human DNA sequence alone, low-
throughput experimental validation remained indispensable to ascertaining whether predicted 
ORFs were truly capable of producing endogenous protein products. 
Annotation of ORFs using direct experimental evidence of ribosome translation is now possible 
through high-throughput ribosome profiling. Ribosome profiling is an experimental technique that 
produces a global, quantitative snapshot of actively translating ribosomes throughout the cell 
[101]. The typical experimental workflow involves treating cells with compounds that inhibit 
translational elongation and immobilize translating ribosomes on RNA transcripts. These RNAs 
are extracted and digested using nucleases that remove RNA fragments unprotected by the 
presence of immobilized ribosomes. After digestion, ribosomal RNA (rRNA) is depleted, and the 
remaining ribosome-protected fragments are sequenced and re-aligned to the genome (Fig 
3.1).  Because translation elongation proceeds with a 3-nucleotide periodicity, this feature can be 












Figure 3.1: Basic experimental workflow for ribosome profiling.  
 
3.2: Pervasive translation in non-canonical open reading frames 
The unanticipated abundance of ribosome-protected fragments mapping outside of known 
annotated protein-coding regions of the genome was a key observation arising from early 
ribosome-profiling studies [102–104]. When mapped back to the genome, many of these 
fragments shared similar characteristics to ribosome-protected fragments in known coding 
regions of the genome, including size distribution and 3-nucleotide periodicity [105]. Together, 
these studies suggested that cellular RNAs previously not thought to encode for functional 
proteins or peptides were nevertheless being translated by ribosomes. As many of these newly 
mapped non-canonical ORFs (ncORFs) were short in length, some suggested that they could 
encode for functional micropeptides which had been previously overlooked in ORF mapping 
studies due to biases favoring ORF annotation with longer sequence lengths [104–107]. 
45 
 
Early examples of functional micropeptides had been characterized in the literature prior to their 
being identified in ribosome profiling data. Early evidence of micropeptide functionality was first 
characterized in yeast, where mutagenesis studies of 247 small ORFs <100 amino acids in length 
identified 22 ORFs required for haploid growth [108]. Specific functional small ORFs were further 
characterized from studies in Drosophila using polysome profiling - a technique which involves 
fractionating cellular mRNAs in a sucrose gradient to extract species bound by multiple 
ribosomes - which identified that select noncoding RNAs without obvious coding potential could 
be enriched from polysome-bound fractions [109]. Among these early examples of translated 
noncoding RNAs, the tarsal-less (tal) gene transcript was found to encode 4 small ORFs capable 
of producing 11-amino-acid-long peptides indispensable for early Drosophila morphogenesis 
[109]. Further investigation of polysome-bound noncoding RNAs from Drosophila identified a 
second polycistronic noncoding RNA (pncr003:2L) encoding two ORFs of length 28 and 29 amino 
acids each producing peptide products involved in regulating cardiac calcium transport [110]. 
Together these functional micropeptides served as early evidence that length-biases in gene 
discovery pipelines may have overlooked an entire class of functional elements encoded within 
sequenced genomes. 
To date, several additional examples of functional micropeptides in the human genome have 
been reported. These include several micropeptides implicated in regulating intracellular calcium 
levels and muscle contraction [111–113], the inflammatory response [114,115], and cellular 
metabolism [116–120]. Although modern ribosome-profiling approaches have uncovered 
widespread evidence translation in thousands of small non-canonical ORFs (ncORFs) in the 
human genome [102,121,122], what fraction of these ncORFs (ncORFs) can produce functional 
micropeptides remains an open question.  
A second possibility is that translation of ncORFs serve regulatory rather than coding functions. 
This regulatory hypothesis is most strongly supported by studies of upstream open reading 
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frames (uORFs). Since uORFs can initiate translation by ribosomes prior to their reaching 
downstream coding sequences (CDS), they are most frequently associated with repressive 
effects on downstream CDS translation [122–124]. Moreover, it has been observed that cis-
regulatory relationships between uORFs and downstream coding sequences are frequently 
maintained across species, but the nucleotide content of these ORFs are not [122,125]. Together, 
this evidence implies that the functional importance of uORF translation is in its regulatory effect 
on downstream protein expression rather than micropeptide encoding. Nevertheless, a few 
examples of uORF-encoded micropeptides which are capable of repressing downstream 
translation initiation at the CDS in a peptide-dependent have also been observed, although this 
phenomenon appears to be the exception rather than the rule [126,127]. More recently, the 
striking pervasiveness of translation outside of canonical protein coding ORFs revealed by 
ribosome profiling has not stopped some from speculating that micropeptides resulting from 
ncORF translation are broadly functional [107]. 
 
3.3: Disrupting upstream translation in mRNAs is associated with loss-of-function in 
human disease 
The classic view of information processing in the cell by gene expression occurs through 
transcription followed by translation. This basic flow is often complicated by regulatory elements 
which confer additional stages of processing and control. In particular, upstream open reading 
frames (uORFs) are segments of 5’UTR mRNA sequences that can initiate and terminate 
translation upstream of protein-coding start codons. Specific uORFs are known to control protein 
expression by tuning translation rates of downstream protein-coding sequences, and potential 
uORFs have been identified in ~50% of all human protein-coding genes [123,128]. 
Translation initiation is the rate-limiting step controlling post-transcriptional gene expression [129], 
and rates of translation initiation can significantly impact mRNA stability [130–134]. Cap-
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dependent translation initiation begins when the 40s ribosomal subunit encounters a start codon 
as it scans along the 5’UTR. At the start codon, the 40s subunit acquires the 60s subunit with 
other translation initiation factors and peptide synthesis begins. Scanning ribosomes 
encountering uORFs may prematurely initiate translation in the 5’UTR; if this occurs, upon 
reaching the uORF termination codon the ribosome may dissociate from the mRNA transcript, or 
the 40s subunit may resume scanning after the 60s subunit is lost. Resumption of scanning leads 
to translation of downstream reading frames only if the necessary translation initiation factors are 
reacquired by the 40s subunit before reaching the downstream start codon. Thus, the spatial 
combination of uORFs and protein-coding start codons can produce different effects on 
translation of the downstream gene.  
Previous analyses of large-scale population data have shown that genetic variants creating new 
uORFs are rare, suggesting that these variants are subjected to strong negative selection due to 
their capacity to cause pathogenic loss-of-function of associated proteins [123,135]. Moreover, it 
has been shown that variants destroying stop codons in translated uORFs are under strong 
negative selection, presumably because the resultant translational readthrough can decrease 
start codon recognition and translation initiation at the coding sequence (CDS) [46]. In contrast, 
less is known about the impact of genetic variation within translated uORFs. Furthermore, recent 
untargeted ribosome-profiling experiments have revealed striking evidence of active translation at 
thousands of uORFs throughout the genome, but the biological significance of this phenomenon 
remains unresolved [123]. 
Here we use translated uORFs mapped through ribosome-profiling experiments and a deep 
catalogue of human genetic variation to characterize patterns of selection acting on single 
nucleotide variants (SNVs) in translated uORF sequences. We assess evidence for the functional 
importance of translation at uORFs, and explore possible phenotypic consequences associated 
with genetic variation in these sequences. Using the allele frequency spectrum of SNVs from 
48 
 
71,702 whole genome sequences in gnomAD, we find that SNVs introducing new stop codons, or 
creating stronger translation termination signals in uORFs are under strong selective constraints 
within 5’UTRs. We propose that these variants are under selective pressure because they disrupt 
translation initiation at downstream protein-coding sequences. We then utilize the Penn Medicine 
Biobank (PMBB) to discover new, robust disease-gene associations using uORF stop-creating 
and stop-strengthening variants and replicate these associations in the UK Biobank (UKB), and 
by gene burden tests aggregating rare protein-coding loss-of-function variants. Finally we validate 
the impact of uORF stop-creating and stop-strengthening variants on protein expression for our 
top phenome-wide significant associations. These data demonstrate that mutations in translated 
uORFs creating new stop codons, or strengthening existing stop codons can contribute to 
disease pathology by changing protein expression. 
 
3.3: Variants introducing new stop codons in uORFs are under strong negative selection 
Since elongating ribosomes must translate uORFs before they reinitiate translation at the CDS, 
we hypothesized that genetic variants introducing new stop codons in translated uORFs could 
impede downstream translation initiation. Because these variants interrupt translation without 
affecting the coding sequence directly, we term them upstream termination codons (UTCs) to 
distinguish them from premature termination codons within protein-coding sequences. 
To estimate the deleteriousness of UTC mutations, we assessed their frequency spectrum in 
gnomAD using the Mutability-Adjusted Proportion of Singletons (MAPS) metric. MAPS compares 
the strength of selection acting against different classes of functional variation by assessing the 
relative enrichment for rare singleton (one sequenced allele) variants in gnomAD, adjusted for 
local mutation rates (see Appendix B). More deleterious groups of SNVs - including premature 
termination codons and essential splice site mutations - show greater enrichment in singletons in 
gnomAD, and consequently have higher MAPS scores. MAPS has previously been used to 
49 
 
assess patterns of selective pressures acting on different classes of variation in both protein-
coding and non-coding regions of the genome [37,45,135–138]. 
Using translated uORFs from 4392 genes identified by deep ribosome profiling of two human cell 
lines (Figure 3.11) [94], we mapped genetic variation from 71,702 whole-genome sequences in 
gnomAD (version 3)[91]. We identified the subset of UTC mutations by selecting SNVs which 
mutated uORF codons to either UGA, UAG, or UAA in the mapped uORF reading frame (Figure 
3.2a). We calculated MAPS scores for these UTC mutations, finding that they are under strong 
negative selection within 5’UTRs, comparable to that of missense mutations in canonical protein-
coding regions of the genome (Figure 3.2b). Indeed, MAPS scores for these variants are 
significantly higher than all uORF variants (Figure 3.2b, P<0.001), sets of uORF variants matched 
by their underlying trinucleotide mutation context (Figure 3.12, P<0.001 - see Appendix B), all 
5’UTR variants creating UTCs outside of mapped translated uORFs (P=0.0441), and stop-
creating variants in ORFs in 3’UTRs, translated pseudogenes, and lncRNAs also mapped by 
ribosome-profiling from the same study (Figure 3.2b P=0.0041, Figure 3.11). Intriguingly, MAPS 
scores were highest for variants predicted to introduce strong (UAA) stop codons that are less 
susceptible to translational read-through [95–97]. In contrast, variants introducing the weaker 
UGA stop codon exhibited MAPS scores that are only nominally higher than MAPS scores for all 
uORF variants (P = 0.2833), suggesting that they may be less deleterious by comparison. To 
account for the possibility that the heightened MAPS scores for UTC mutations resulted from 
overlap between 5’UTRs and annotated coding sequences in different mRNA isoforms, we 
repeated this analysis excluding all uORF variants overlapping with any annotated CDS 
sequence. Re-calculated MAPS scores with all CDS-overlapping variants removed remained 
essentially unchanged (Table 3.2), ruling out the possibility that the enrichment in rare variation 
for UTC mutations is driven by selection on coding sequences. Additionally, we previously 
observed that variants destroying the central guanine of putative G-quadruplex forming 
sequences exhibit heightened MAPS scores in UTRs. We repeated this analysis with all potential 
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G-quadruplex disrupting variants (n = 57) excluded, seeing a negligible effect on MAPS scores 
for all UTC mutations (MAPS = 0.0377, 95% CI: 0.0196-0.0557). Overall, the strong selective 
pressure to remove UTC mutations implies that these variants are also more likely to have 
functional biological consequences. 
 
 
Figure 3.2: Stop-introducing and stop strengthening mutations in translated uORFs are 
under strong negative selection. (a) Examples of possible stop-gained (UTC) or stop-
strengthened mutations in translated uORFs. (b) Mutability-Adjusted Proportion of Singletons 
(MAPS) scores for different classes of stop-introducing mutations within translated uORFs. Grey, 
orange, and purple dashed lines represent MAPS scores for synonymous, missense, and 
predicted loss-of-function (pLOF) SNVs affecting canonical protein-coding sequences in 
gnomAD. (i) MAPS scores for non-uORF variants including all 5’UTR SNVs, stop gained 
mutations in ncORFs, and all 5’UTR stop gained mutations (ii) MAPS scores for all uORF SNVs 
and stop gained mutations in uORFs show that uORF UTC mutations are significantly enriched 
for singletons. This is also observed for UAA-creating, and stop-strengthening SNVs in translated 
uORFs. Error bars represent bootstrapped 90% confidence intervals.  
3.4: Translated uORFs use weak stop codons 
Stop codons have different translation termination efficiencies in both prokaryotes and 
eukaryotes, with the hierarchy following the general pattern of UAA > UAG > UGA [139,142,143]. 
Given the observed selection against UTC mutations in translated uORFs, and in particular 
against UAA-introducing variants, we next asked whether stop codon usage by translated uORFs 
is distinct from the background distribution of UGA, UAG, and UAA trinucleotides in 5’UTRs. To 
perform this comparison, we determined the relative frequency that UGA, UAG, or UAA 
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trinucleotide sequences appeared within non-translated 5’UTR sequences, and compared this 
frequency to the distribution of stop codons used in translated uORFs. To further control for the 
possibility that translated-uORF containing UTRs might have significantly different background 
nucleotide distributions, we also assessed the relative frequency of UGA, UAG, or UAA 
trinucleotides from uORF-containing UTRs with translated uORF sequences excluded. Strikingly, 
we find that translated uORF stop codons are significantly depleted of UAAs compared to 
background UTR distributions (Figure 3.3a), suggesting that weaker stop-codons (UGA, UAG) 
are preferred (permutation P<0.001 compared to all UTRs, P<0.001 compared to uORF-
containing UTRs). Indeed there are approximately 45% less uORF UAA stop codons compared 
to the relative frequency of UAA trinucleotides in adjacent untranslated UTR sequences (uORF-
UAA=19%, matched UTR-UAA=35% - Table 3.3). In contrast, UGA stop codons are enriched 
within translated uORFs compared to non-translated UTR sequences (permutation P<0.001 
compared to all UTRs, P<0.001 compared to uORF-containing UTRs). 
 
Figure 3.3: Translated uORFs tend to use weak stop codons. (a) Relative frequencies of 
trinucleotides used as uORF stop codons compared to untranslated regions of uORF-containing 
5’UTRs, or all 5’UTRs shows uORFs are significantly enriched for weaker (UGA, UAG) stop 
codons and depleted of the UAA stop codons compared to control sequences. Error bars 
represent 95% bootstrapped confidence intervals. (b) Proportion of strongly conserved (phyloP > 
2) bases by phyloP scores from 100-way vertebrate alignments for uORF stop-creating, non-
uORF stop-creating in uORF-containing UTRs, and non-uORF stop-creating in all UTR genomic 
positions. Error bars represent 90% bootstrapped confidence intervals. 
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Given the depletion of UAA-stop codons in translated uORFs, we next asked whether variants 
changing weaker stop codons (UGA, UAG) to UAA were also enriched for singletons. Compared 
to synonymous and missense variation within the protein-coding genome, we find that the MAPS 
metric for stop-strengthening variants is significantly higher (Figure 3.2b-ii). This difference 
remained significant compared to uORF variants matched by trinucleotide context, indicating that 
this effect is specific to uORF stop codons (P=0.012, Figure 3.12). Given that UAA codons can 
facilitate greater termination efficiency and more rapid ribosomal dissociation from mRNAs 
compared to UAG and UGA codons [139,144,145], these results are consistent with the 
possibility that stronger stop codons in uORFs can also increase the efficiency of translation 
termination in the 5’UTR. Thus, like UTC mutations, stronger stop codons in uORFs may be 
disfavored because they decrease the probability that ribosomes reinitiate translation at 
downstream coding sequences. 
 
3.5 Genomic positions that can create new stop codons in uORFs are conserved 
Since the power of MAPS estimates are limited by the number of variants observed in gnomAD, 
we assessed the evolutionary conservation of each possible uORF stop-creating position as 
complementary evidence for their functional significance. For this, we compared the distribution of 
phyloP scores across potential uORF-stop-creating positions derived from the UCSC 100-way 
phyloP vertebrate alignment [38].. Specifically, for each potential new stop site, we compared the 
proportion of genomic positions with a phyloP score of > 2 - corresponding to strong conservation 
across multi-vertebrate alignment - versus those positions that were not strongly conserved 
(phyloP < 2). A similar approach has been used to show that genomic positions with the potential 
to produce new uORFs are strongly conserved across vertebrates [135]. 
We performed several assessments of phyloP scores across 5’UTR contexts. Consistent with our 
MAPS analysis, potential stop-creating positions in translated uORFs are also more likely to be 
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conserved compared to UTR positions matched by distance to the downstream coding sequence. 
This difference remained significant even when compared to potential stop-creating positions in 
5’UTR sequences adjacent to (but not within) translated uORFs (Figure 3.3b). Strikingly, 
conservation at each stop-creating position within mapped translated uORFs mirrored the 
strength of stop-codon contexts, with a positive correlation between the strength of the potential 
stop codon introduced and the proportion of uORF genomic positions that are conserved. This 
trend was not observed for non-translated 5’UTR contexts (Figure 3.3b). In all cases, the 
proportion of conserved bases for each class of potential stop-creating variant was significantly 
higher than those positions in all 5’UTRs, and particularly within untranslated regions of 
translated-uORF containing UTRs (P<0.001, Figure 3.3b). Moreover, the proportion of highly 
conserved bases at possible stop-creating positions increased in association with increasing 
gene constraint, as determined by the gnomAD LOEUF score, and remained significantly higher 
than non-uORF 5’UTR stop-creating positions (Figure 3.13). Together, these complementary 
analyses support our initial findings that UTC mutations are under strong negative selection within 
the human genome, and further strengthens the evidence that UTC mutations may functionally 
disrupt protein expression. 
 
3.6: Upstream open reading frames are not under strong selection to maintain amino 
acid identity 
Multiple transcriptome-wide ribosome profiling studies have proposed that some uORFs can 
encode functional micropeptides with important cellular roles [106,107,121]. This has fostered 
significant interest in the possibility that translated, non-canonical ORFs represent an overlooked 
class of potentially functional micropeptides with biological activity independent of the 
downstream protein-coding sequences [107,146]. If many uORFs encoded functional 
micropeptides, the pattern of constraint against UTC mutations might also reflect selection to 
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preserve micropeptide function rather than downstream translation initiation. To address this 
possibility, we asked whether uORFs broadly exhibit similar constraints against missense 
variation, compared to known protein-coding regions of the genome, that could imply peptide 
functionality. We compared MAPS scores for predicted missense versus synonymous mutations 
in translated uORFs to those in canonical protein-coding regions of the genome (Figure 3.4). The 
MAPS scores for missense mutations in uORFs were significantly lower than that of missense 
mutations in canonical protein-coding regions of the genome, and not significantly higher than 
MAPS scores for synonymous variants in translated uORFs (P=0.7118, Figure 3.4a-iv). These 
results indicate that selection to maintain amino acid identity in uORF-encoded micropeptides is 
weak compared to canonical protein-coding sequences. As an additional control, we computed 
MAPS scores for predicted missense and synonymous mutations in 693, 1188, and 276 
translated non-canonical ORFs (ncORFs) mapped by ribosome profiling in 3’UTRs (dORFs), 
long-noncoding RNAs, and pseudogenes respectively, as these sequences are not thought to 
broadly encode for functional peptides. Similar to uORFs, predicted missense variants in these 
additional ncORFs were not significantly higher than predicted synonymous variants by MAPS 
score (dORFs P=0.3532; lncRNAs P=0.7777, pseudogenes P=0.4523 Figure 3.4a-i-iii). 
Since many translated uORFs are short, we asked whether longer uORFs might exhibit greater 
selection against missense variants compared to shorter uORFs. To test this possibility, we 
divided uORFs into long sequences >118 codons comprising the top 25% longest mapped 
uORFs, and short uORFs <118 codons in length. MAPS scores for missense variants in long 
versus short uORFs yielded no evidence of significant constraint acting on amino-acid changing 





Figure 3.4: ncORFs do not exhibit strong selective pressure to maintain amino acid 
identity. MAPS scores for single nucleotide variants within each ncORF category separated by 
predicted consequence (synonymous or missense) in each ORF. (i-iv) Allele frequencies for 
predicted missense SNVs are not significantly enriched for singletons than those for predicted 
synonymous SNVs. (v) MAPS scores are no different for long uORFs (> 118 codons) compared 
to the rest (short). Grey, orange, and purple dashed lines represent MAPS scores for 
synonymous, missense, and predicted loss-of-function (pLOF) SNVs affecting canonical protein 
coding sequences in gnomAD. Error bars represent bootstrapped 90% confidence intervals. 
Surprisingly, we observed that MAPS scores for both synonymous and missense variants in 
translated uORFs deviated significantly from all 5’UTR variation (Figure 3.4a-iv). These 
heightened MAPS scores implied that uORF variants are under increased negative selection 
compared to all 5’UTR variants. The absence of similar effects for variants in dORFs, lncRNAs, or 
translated pseudogenes implies that this enrichment in singletons is unique to translated uORFs. 
One possibility is that synonymous variation in uORFs reflect selective pressures to maintain 
translational efficiency by preserving codon optimality. Messenger RNAs that are enriched with 
more optimal codons are both more stable, and more efficiently translated by ribosomes [147]. 
Like UTC mutations, uORF mutations introducing suboptimal codons could therefore slow 
translational elongation and impede downstream translation initiation at the CDS. Indeed, 
mutations introducing suboptimal codons in translated uORFs have been shown to disrupt 
translation initiation at downstream coding sequences [148–150], and more generally 5’UTRs are 
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under selective pressures to maintain their capacity for facilitating translation initiation at the CDS 
[151,152].  
 
Figure 3.5: Synonymous and missense variants in translated uORFs are under selective 
pressure to maintain codon optimality. (a) Translated uORF variants ranked by predicted 
change to codon optimality using codon stability coefficient (CSC) scores from SLAM-seq (red = 
decreasing, blue = increasing) [110]. Grey dotted line denotes boundary separating optimality 
increasing versus decreasing SNVs. (b) MAPS scores for SNVs separated by predicted 
consequence on codon optimality shows heightened constraint against decreasing optimality 
variants, while variants increasing optimality are indistinguishable from all 5’UTR variants. Error 
bars represent bootstrapped 90% confidence intervals. 
To test whether mutations in translated uORFs are constrained to maintain codon optimality, we 
asked if MAPS scores for mutations predicted to decrease codon optimality differed from those 
that increased codon optimality (Figure 3.5a). Using experimentally determined codon-stability 
coefficients (CSCs) [153], we matched each uORF SNV with its predicted consequence to codon 
optimality, and compared MAPS scores for optimality-increasing versus optimality-decreasing 
SNVs. As expected, SNVs increasing codon optimality were indistinguishable from all 5’UTR 
variants (P=0.1929, Figure 3.5b). In contrast, variants predicted to decrease codon optimality had 
significantly higher MAPS scores (P<0.001), although the magnitude of this difference is 
moderate compared to UTC mutations (Figure 3.3b). This effect remained significant regardless 
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of whether variants were predicted to cause synonymous or missense mutations (P=0.0125 for 
synonymous; P=0.009 for missense), and was notably absent for translated ORFs in 3’UTRs, 
lncRNAs, and pseudogenes (Figure 3.5b, Figure 3.14). Furthermore, this pattern of increased 
constraint against optimality-decreasing mutations was robust to the use of CSC scores derived 
from alternative experimental approaches across several cell lines (Figure 3.15) [153]. Together, 
these observations further support the hypothesis that natural selection acts to maintain the 
capacity for translational initiation at downstream coding sequences by preserving translational 
elongation efficiency in uORFs. 
3.7: uORF start codons are conserved and under strong selective pressure 
The finding of heightened selection against translation-interrupting variants in uORFs raises the 
question of why translated uORFs continue to persist in a large fraction of human genes. 
Evidence that uORF-CDS organization, and the strength of uORF repression is strongly 
conserved across vertebrates, suggests that translation at uORFs is maintained to regulate 
downstream translation initiation [122]. Moreover, variants destroying uORF start codons have 
been implicated in the development of cancer [154]. To provide further genetic evidence that 
translation at uORFs is maintained by selection, we asked whether allele frequencies for variants 
affecting uORF start codons also exhibited strong selection to maintain their capacity for 
translation initiation. Using the MAPS metric, and genome-wide phyloP scores, we evaluated 
patterns of variation affecting uORF start codons. Since many translated uORFs begin with non-
canonical start codons (Figure 3.6a-i), we distinguish between variants maintaining the start 
context by affecting the first position of the NUG trinucleotide from those that disrupt translation 
initiation by mutating the last two nucleotides in the uORF start codon (Figure 3.6a-ii). As 
expected, start-maintaining variants are no more enriched for singletons in gnomAD compared to 
synonymous protein coding variants. In contrast, start-disrupting mutations are enriched for 
singletons at a level comparable to that of protein-coding missense and UTC mutations (Figure 
3.7). The heightened pressure to maintain translational initiation at uORF start codons is similarly 
58 
 
reflected in phyloP scores for uORF start-disrupting genomic positions compared to distance-
matched UTR controls (P < 0.001), and uORF-matched controls (P < 0.001, Figure 3.8). These 
data show that translation initiation at uORFs is evolutionarily constrained in humans, and are 
consistent with previous reports that uORF start codons are frequently conserved across species. 
Taken together, our analyses of genetic variation in gnomAD show enrichment for rare allele 
frequencies in the frequency spectra of uORF start-disrupting, stop creating, and stop-
strengthening mutations. Results from our analyses indicate that these classes of variation are 
under a heightened degree of negative selection, and imply that processes of translation 




Figure 3.6: Start codon usage for uORFs mapped by ribosome profiling. (i) Distribution of 
start codon usage for experimentally mapped translated uORFs, and (ii) possible consequences 




Figure 3.7: MAPS scores for uORF start disrupting variants. (i) MAPS scores for start-
disrupting SNVs are compared to uORF variants matched by trinucleotide mutation context. (ii) 
Start-disrupting SNVs for short (< 20 codons) uORFs are under stronger negative selection 
compared to start-disrupting variants for long (>= 20 codons) uORFs. Error bars represent 





Figure 3.8: PhyloP estimates for possible start codon disrupting positions. uORFs start 
disrupting positions are compared to all uORF SNVs, UTR-matched start-disrupting positions, 
and uORF-matched start-disrupting positions in translated uORFs. Start-disrupting genomic 
positions of short uORFs are more strongly conserved by phyloP scores compared to matched 
start-disrupting positions within uORFs. Error bars represent bootstrapped 90% confidence 
intervals. 
3.8: uORF-disrupting variants associate genes with new disease phenotypes 
The heightened MAPS score for UTC mutations suggests that they are also likely to be 
functional. To explore the possibility that UTC and uORF stop-strengthening mutations might 
contribute functionally to human disease susceptibility, we performed a phenome-wide 
association study (PheWAS) of predicted uORF-disrupting variants using the Penn Medicine 
Biobank (PMBB) - a large academic biobank with exome sequencing linked to EHR data for 






Table 3.1: Significant novel associations in PheWAS of Penn Medicine BioBank 
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*As of the Gencode 32 release the 5’UTR PMVK annotation (September 2019) was shortened to 
exclude this uORF; however inspection of the raw ribosome profiling reads from Ji et al. [121] in 
conjunction with nearby transcription start sites annotated in FANTOM5 confirm the presence of a 
longer PMVK 5’UTR isoform (Figure 3.17). †The stop-strengthening variant in BCL2L13 affects a 
minor transcript isoform, and is also annotated as a synonymous mutation on the primary 
BCL2L13 transcript. 
 
Using exome sequencing from the PMBB, we identified heterozygous and homozygous 
individuals carrying UTC and stop-strengthening mutations. For the former class, we focused on 
variants introducing UAA stop codons, as the heightened MAPS score for such variants implied 
these mutations would be most deleterious. Filtering for variants with at least 5 heterozygous 
carriers with high-quality genotype, we identified 10 variants matching the above criteria (6 stop-
strengthening mutations, 4 UAA-UTC mutations). For each of these mutations we performed a 
single-variant PheWAS across 800 EHR phenotypes. Of those 10 candidates, 6 passed an FDR 
threshold of 0.1 (P<1.25e-4) used in previous PheWAS studies [156,157], including 5/6 of the 
stop-strengthening variants and 1/4 of the UAA UTCs. Even more strikingly, two of these six 
variants passed a highly conservative Bonferroni correction (P<6.25e-6), both being uORF stop-
strengthening variants. The stop-strengthening variant in PMVK was associated with increased 
risk of Type 1 diabetes while the stop-strengthening variant in VPS53 was associated with a 
protective effect against anxiety disorders (Figure 3.9, Figure 3.16, Table 1, Table 3.4). Notably, 
of the identified phenotype-associated variants, only VPS53 is annotated as a cis-eQTL in the 
latest GTEx release (version 8). 
To replicate associations from our exploratory analysis in the PMBB, we performed additional 
single-variant association analyses for each of the 6 significant variant-phenotype associations in 
the UK Biobank (UKB). Direct replication using the original significant 4- or 5-digit ICD-9 code 
from the PMBB was tested for each variant-phenotype association. Where there were insufficient 
case numbers in the UKB, we used the broader 3-digit ICD-9 code. Out of six novel associations 
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reaching FDR < 0.1, one (rs140799351) showed P < 0.05 in the UKB at the 5-digit ICD code 
level, reaching study-wide significance (Table 3.1, Table 3.5). For the remaining putative novel 
associations, the VPS53 uORF stop-strengthening variant did not replicate, although the direction 
of effect is consistent with results from the PMBB. Finally variants in SHMT2 could not be 
replicated because there were fewer than 20 cases in the UKB cohort, and MOAP1 could not be 






Figure 3.9: Phenome-wide association study (PheWAS) of predicted stop-strengthening 
variant in a translated uORF in PMVK. PheWAS plot of translated uORF stop-strengthening 
variant in the  5’UTR of PMVK (N = 65 carriers) in the Penn Medicine BioBank. ICD-9 and ICD-10 
Phecodes are organized and plotted by category on the X-axis. The solid red line represents the 
threshold for Bonferroni-adjusted significance (P=6.25e-6) and the red dashed line represents the 
FDR threshold (P=1.25e-4). The direction of each arrowhead corresponds to increased risk (up) 
or decreased risk (down).  
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3.9: Disease-associated uORF variants change protein expression 
To elucidate the possible biological consequences of UTC and stop-strengthening mutations, we 
selected three PheWAS association signals in the discovery analysis for functional assessment. 
To determine if these variants could affect protein expression, we measured the expression of a 
set of dual-luciferase reporters in HEK293T cells for PMVK, VPS53, and the BCL2L13 uORF 
variants. We compared the expression of the wild-type 5’UTR sequence for PMVK, VPS53, and 
BCL2L13 cloned upstream of a Firefly Luciferase ORF to two variant sequences - one with the 
predicted uORF start codon removed, and a second sequence with the PheWAS-significant stop-
strengthening mutation inserted. For VPS53, we also tested the effect of a mutation changing a 
tryptophan UGG codon to a UAG UTC (Figure 3.10b). Across all constructs, we observed a 
significant reduction in expression of the downstream ORF when the PheWAS-significant stop-
strengthening mutation was introduced (Figure 3.10). Introducing a new UTC in the 5’UTR of 
VPS53 also significantly reduced reporter protein expression relative to the wild-type sequence. 




Figure 3.10: Reporter gene assays for translated uORF stop-introducing and stop-
strengthening variants.  Dual-luciferase reporter assay quantifies relative expression for uORFs 
with UTC and stop-strengthening mutations associated with EHR phenotypes by PheWAS. 
Experimental 5’UTRs for (a) PMVK, (b) VPS53, and (c) BCL2L13 for uORF KO, stop-
strengthened, or stop-introduced variants are shown. Bars represent co-transfected Firefly to 
Renilla Luciferase luminescence ratios normalized to associated wild-type 5’UTRs in HEK293T 
cells measured 48 hours post-transfection. Significant P-values from one-sample T-test for each 
condition denoted by * (>0.05), ** (>0.01), and *** (>>0.001). Error bars represent mean + S.E.M. 
of at least 3 independent experiments. 
In all the tested constructs, UTC and stop-strengthening mutations decreased relative Firefly 
expression. These data are consistent with the hypothesis that UTC or stop-strengthening 
mutations are under negative selection because they decrease the probability of translation 
initiation at downstream coding sequences. These results are congruous with our genetic 
analysis, and imply that UTC and stop-strengthening mutations represent a new class of 
functional variation in 5’UTRs capable of causing loss-of-function of downstream coding genes. 
3.10: Replication of novel associations by loss-of-function gene-burden studies 
Results from reporter-gene experiments showed that UTC and stop-strengthening mutations 
could decrease expression of the downstream protein for PMVK, VPS53, and BCL2L13. Our 
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findings implied that uORF UTC and stop-strengthening mutations cause phenotypic 
consequences through potential loss-of-function of the downstream protein-coding gene. To 
further validate this hypothesis, we performed a gene burden test by aggregating rare loss-of-
function protein-coding variants in the PMBB and UKB for each significant uORF-PheWAS 
association. These studies could confirm that predicted loss-of-function in the protein coding 
sequence of the uORF-regulated gene causes the same phenotype as the uORF UTC or stop-
strengthening mutations.  Indeed, similar loss-of-function gene burden approaches using rare 
protein-coding variants have successfully been applied to identify both known and new gene-
disease associations in the PMBB and UKB [155,158].  
Of six PheWAS-significant associations uncovered in our discovery analysis (FDR<0.1), two 
associations were replicated by an independent loss-of-function gene burden test in either the 
UKB or PMBB. The associations between PMVK and diabetes, and SHMT2 and diseases of the 
salivary gland, were replicated in the UKB and PMBB respectively (PMVK P=0.00727, SHMT2 
P=0.005515, Table 1, Table 3.5). Although no significant LOF-burden association for PMVK was 
replicated in the PMBB, predicted loss-of-function of PMVK was nominally associated with 
impaired fasting glucose (P=0.0235). A second uORF-disease association was replicated for 
NALCN and the parent 3-digit parent PheCode of disorders of plasma protein metabolism in the 
UKB (P=0.0264). Gene-disease associations for BCL2L13 could not be replicated in either the 
PMBB or UKB due to lack of carriers for predicted loss-of-function variants. Ultimately this 
analysis confirmed that loss-of-function gene burden tests using protein-coding variants are 
associated with the same phenotype for two uORF stop-strengthening mutations. This evidence 
of allelic heterogeneity for these phenotypes further strengthens the likelihood that uORF stop-
strengthening variants can cause loss-of-function of downstream protein-coding genes. 
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3.11: Summary and future directions 
By combining large databases of human genetic variation with ribosome profiling, we identified 
two new categories of mutations in 5’UTRs capable of causing loss-of-function in downstream 
coding genes. These mutations either introduce upstream termination codons in uORFs or 
strengthen uORF stop sites. Given that ~50% of human protein-coding genes are estimated to be 
under translational control by uORFs, these findings provide a novel framework for interpreting 
the functional significance of 5’UTR variation for a large fraction of human genes.  
Using these mutations, we additionally identified new gene-disease associations in the PMBB 
and replicated one of these associations in independent single-variant association tests in the 
UKB. Two associations involving stop-strengthening variants in PMVK and SHMT2 and one 
involving a UTC in NALCN were also replicated using protein-coding mutations in loss-of-function 
gene burden tests. These results provide independent validation of uORF variant-phenotype 
associations uncovered through the PMBB discovery analysis and demonstrate that uORF stop-
strengthening and UTC mutations associate with the same phenotype as predicted loss-of-
function coding mutations in downstream coding sequences. In support of these conclusions, we 
have shown that introducing UTCs and stop-strengthening mutations in translated uORFs 
decreases protein expression of downstream genes in reporter assays. These findings establish 
that uORF UTC and stop-strengthening mutations can have functional consequences on protein 
expression and are associated with disease in humans. If we assume that pathogenic UTC or 
stop-strengthening mutations are under similar selective pressures as pathogenic loss-of-function 
variants in protein-coding regions of the genome, we estimate that approximately 24% (90% CI 
21-28%) of uORF-containing genes may be affected by UTC and stop-strengthening mutations 
with severe pathogenic consequences (3.13: Suppl. Note). Moreover, if we assume that 
missense mutations in functional uORF micropeptides are similarly enriched in singletons as in 
protein-coding regions of the genome, we estimate that ~5-15% of translated uORFs are under 
constraint for amino acid function (3.13: Suppl. Note). This latter estimate is consistent with 
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recent CRISPR screens reporting a statistically significant decrease in growth phenotypes for 
~14% (157/1098) of uORF-specific knockouts across two cell lines when the CDS was preserved 
[107]. Finally, of the 4392 genes with translated uORFs used for this analysis, 1121 (26%) are 
also annotated as having pathogenic coding sequence variants in ClinVar, suggesting that UTC 
and stop-strengthening mutations in these genes may have additional utility for the diagnosis of 
rare disease.  
Our results suggest uORF translation has broad roles in regulating CDS translation. Translation 
initiation is rate-limiting for protein production and selection against mutations disrupting 
translation elongation (UTCs) or termination at uORFs (stop-strengthening variants) may reflect 
the importance of preserving translation initiation efficiency at the CDS. This suggested mode of 
regulation is in-line with observations that cis-regulatory relationships between uORFs and 
downstream coding sequences are frequently conserved across vertebrates while features 
conferring strong uORF repression are less maintained [122,124]. For stop-strengthening 
variants, the increased translation termination efficiency could accelerate ribosomal release from 
the mRNA transcript, thus decreasing downstream CDS translation. This mechanism is 
consistent with previous data in human cell lines showing that decreased translation termination 
efficiency by global knockdown of eRF3A increases translation of genes under uORF-repression 
[159, 160]. For UTC mutations, the introduction of stop codons in the uORF may lead to either 
ribosome stalling and subsequent collisions that further repress CDS expression [161,162]. This 
early translation termination in uORFs might also facilitate greater rates of premature ribosome 
release from the mRNA transcript, or can lead to nonsense mediated decay (NMD). While a 
handful of translated uORFs that activate NMD have been described in the literature [163–165], 
whether uORF-activated NMD broadly regulates protein expression remains an open question. 
Indeed, depletion of UPF1, a central component of the canonical NMD pathway, produced only 
minimal changes in uORF-containing mRNAs abundance in human cell lines [159]. 
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The capacity for translated uORFs to produce functional micropeptides independent of regulating 
CDS expression remains an area of active investigation. In canonical protein-coding regions of 
the genome, amino acid substitutions in critical protein domains can be highly deleterious for 
cellular functioning and fitness. Previous studies have found that uORF-encoded peptides show 
evidence of amino acid conservation using statistical tests relying on a null hypothesis of neutral 
selection [121]. It is unclear if the conclusions drawn from these approaches account for the 
possibility that codon-optimality constrains variation within uORFs rather than amino acid identity. 
In contrast, we do not observe similar constraints on missense mutations in translated uORFs, 
suggesting that amino acid substitutions within most uORF-encoded micropeptides are well-
tolerated in humans. This was also the case for other non-canonical translated ORFs, including 
3’UTR ORFs, pseudogenes, and lncRNAs, that are not thought to widely encode for functional 
micropeptides. Although a handful of functional micropeptides have been identified previously, 
our analysis implies that most ncORFs do not produce peptide products whose function depends 
on their amino acid composition. It is also important to note that ribosomes are among the most 
abundant proteins within cells, occupying approximately 5% of the entire intracellular volume 
[166]. As improvements in ribosome profiling facilitate deeper characterization of the translatome, 
observations of widespread translation in non-canonical ORFs should be interpreted cautiously in 
light of potential functionality. 
Interestingly, bi-allelic loss-of-function mutations in SHMT2 have recently been described in a 
novel brain and heart developmental syndrome involving spastic paraparesis and ataxias [167]. 
Indeed, in addition to the phenome-wide significant association with diseases of the salivary 
gland uncovered in our study, the SHMT2 uORF stop-strengthening variant was nominally 
associated with several Phecodes related to cardiac and movement disorders in the PMBB 
(Table 3.7), including Congenital anomalies of the great vessels (ICD 747.13, P = 0.0117), 
Abnormal involuntary movements (350.1, P = 0.0238), Abnormality of gait (350.2, P = 0.02575), 
Mobitz II AV block (426.22, P = 0.03432), and Arrhythmia (cardiac) NOS (427.5, P = 0.04977). 
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These additional nominal associations suggest that SHMT2 uORF variants may be capable of 
contributing to similar phenotypic consequences as described in loss-of-function mutation 
carriers, however further studies are needed to investigate this possibility. The novel association 
between stop-strengthening and pLOF variants in PMVK with diabetes further strengthens 
existing genetic and epidemiological evidence linking the mevalonate pathway to diabetes. PMVK 
encodes for phosphomevalonate kinase, an enzyme in the mevalonate pathway catalyzing the 
conversion of mevalonate-5-phosphate to mevalonate-pyrophosphate downstream of HMG-CoA 
reductase. Multiple randomized clinical trials have shown that inhibiting HMG-CoA reductase with 
statins increases the risk of developing new-onset type 2 diabetes in a dose-dependent manner, 
although the mechanism driving this association has remained elusive [168–170]. Moreover, 
genetic variants in and near the HMGCR gene that are associated with lowered LDL cholesterol 
levels have been similarly shown to confer an increased risk of developing diabetes [171,172], 
suggesting that decreased HMGCR activity contributes to diabetes pathogenesis. Our data is the 
first to establish a putative link between PMVK and diabetes. Given the shared involvement of 
PMVK and HMGCR genes in the mevalonate pathway, it is possible that variants in both these 
genes confer an increased risk of diabetes through a similar mechanism, however additional 
studies will be needed to further elucidate the precise relationship between PMVK and diabetes. 
A limitation of our analysis is that we cannot directly assess the impact of additional factors on 
uORF-mediated translational regulation. As an example, a pathogenic UTC mutation in the U2HR 
gene has previously been reported to confer gain-of-function in Marie Unna hereditary 
hypotrichosis [173]. However, missense variants in this uORF also confer gain-of-function effects, 
suggesting that these mutations contribute to pathology through disrupting a functional 
micropeptide. Indeed, previous studies have shown that a multitude of factors may impact uORF 
regulatory function and dissecting these effects remains a challenge for future studies.  
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Finally, we note that being a hospital-based biobank, participants in the PMBB are generally less 
healthy than the general population. As phenotypes within broader disease Phecode families are 
often highly correlated, we sought to replicate associations uncovered in the discovery analysis 
by first testing for a specific hypothesis-driven phenotype association in addition to related 
phenotypes in the corresponding Phecode families. We recognize that controlling for Type 1 error 
in this framework remains challenging. However, to remedy this we sought additional confidence 
by further replicating significant uORF-variant associations through loss-of-function gene-burden 
analyses. Moreover, the relative enrichment in diseased individuals in the PMBB may account for 
why few associations discovered in our analysis of the PMBB are replicated in the UKB which 
contains a healthy volunteer selection bias [174]. Indeed, we were unable to test for an 
association for two of the six PMBB associations due to an inadequate number of individuals 
having the phenotype in UKB. As hospital-based biobanks become more prevalent these 
unreplicated associations should be revisited and confirmed. 
Understanding and interpreting the impact of noncoding genetic variation is a fundamental 
challenge in biology. Many mutations affecting uORFs are known to cause disease [175–178], 
but until now, most studies have focused on mutations which abolish start codons, stop codons of 
existing uORFs, or those that create new inhibitory uORFs. By examining patterns of genetic 
variation within translated uORFs, we have uncovered two new categories of variation affecting 
5’UTRs that may lead to loss-of-function in associated genes. We have used these variants to 
identify new gene-disease associations, and provide evidence for their ability to impact 
downstream gene expression. Our approach demonstrates the power of integrating population-
scale databases of human genetic variation with cellular-scale -omics data to identify new 
patterns of how variation impacts regulatory elements. Taken together, our data broadens the 
scope of functional translational regulation by uORFs in the transcriptome and establishes new 




3.12: Supplementary Figures and Tables for Disrupting upstream translation in mRNAs 
is associated with human disease 
 
 
Figure 3.11: Distribution of protein coding ORFs, uORFs, and other non-canonical ORFs 
mapped by ribosome profiling from Ji et. al paper [121]. dORFs represent ORFs mapped in 
3’UTRs, lncRNAs represent ORFs mapped in long-noncoding RNAs, and pseudogenes represent 





Figure 3.12: MAPS scores for uORF UTC-creating and stop-strengthening variants 
compared to non UTC-creating or stop-strengthening uORF variants matched by 
trinucleotide mutation context. Error bars represent bootstrapped 90% confidence intervals. 
 
 
Figure 3.13: PhyloP scores for possible UTC-creating positions and gnomAD protein-
coding constraint. PhyloP scores in translated uORFs (red) compared to 5’UTR sequences 
(black) across all sextiles of gene constraint as determined by gnomAD LOEUF scores (1 being 








Figure 3.14: Optimality changing MAPS scores for SNVs in dORFs (3’UTRs), pseudogenes, 






Figure 3.15: MAPS score for optimality changing variants using different optimality scores. 
MAPS dependence on whether a SNV increases or decreases codon optimality in uORFs is 
robust to changing CSC-scores used to calculate codon optimality across 293 cell lines using the 
orfome approach, and from retinal pigment epithelium cells with CSC-scores calculated using 





Figure 3.16: PheWAS plot of VPS53 stop-strengthening variant. Red solid line indicates 





Figure 3.17: Change in PMVK 5’UTR annotation as of September 2019 Gencode 32 release. 
The longer 5’UTR isoform for PMVK is supported by transcription start-site mapping from 
FANTOM5, and by the remapped ribosome-profiling reads (top, black) from GSE65885. 
 
Figure 3.18: PheWAS plot of BCL2L13 stop-strengthening variant. Red solid line indicates 





Figure 3.19: PheWAS plot of NALCN UAA UTC variant. Red solid line indicates Bonferroni 




Figure 3.20: PheWAS plot of SHMT2 stop-strengthening variant. Red solid line indicates 






Figure 3.21: PheWAS plot of MOAP1 UAA UTC variant. Red solid line indicates Bonferroni 





Figure 3.22: Luciferase experiments for PMVK and VPS53 plasmid Constructs showing 



















Table 3.2: uORF UTC / Stop-strengthening MAPS analysis with all CDS-overlapping 
variants removed. 
 
Table 3.3: Relative frequencies of TGA, TAG, and UAA trinucleotides across different 
5’UTR sequence contexts 
 
Table 3.4: Minor allele frequencies for all PheWAS-significant variants tested in discovery 







Table 3.5: PheWAS replication analyses phenotypes tested 
 






















































































































































Table 3.7: Nominal cardiac and movement disorder associations with SHMT2 stop-









3.13: Supplementary Note: Estimating the proportion of uORFs that may cause 
pathogenic loss-of-function equivalent consequences in ClinVar disease genes 
 
We assume that MAPS score for UTC and stop-strengthening variants in uORFs represent the 
combination of variants from uORFs where loss-of-function is well-tolerated, and those from 
uORFs where loss-of-function is not tolerated (has severe impact on fitness). In other words, the 
MAPS score is a mixture of variants that are not under selective pressure, and variants that are 
under comparable selective pressure to predicted loss-of-function variants in protein-coding 
regions of known disease-associated genes. 
Under this assumption we design a simulation study to model the association between the 
proportion of pathogenic uORFs and MAPS scores for all uORF-disrupting (UTC and stop-
strengthening) variants using variants from protein-coding sequences. We calculate a distribution 
of MAPS scores for each simulated proportion of uORFs capable of harboring pathogenic loss-of-
function variants as described in Figure 3.23. 
Specifically the approach is to: 
1. Randomly select ~4000 genes (approx. number of genes with uORFs) from genes in 
ClinVar with annotated pathogenic consequences 
2. Partition these genes to a sub-fraction of “TRUE LOF” (10%, 20%, 30%, ...) and a sub-
fraction of “FALSE LOF”. The “TRUE LOF” genes will be contributing protein-coding LOF 
variants to the MAPS score in gnomAD 
3. “FALSE LOF” genes will be contributing synonymous variants annotated in gnomAD   
4. Calculate MAPS score for this mixed set of TRUE LOF and synonymous variants 






Figure 3.23: Sampling procedure to generate MAPS scores to model the proportion of 
uORFs where UTC or stop-strengthening variants are capable of having pathogenic 
consequences.  
 
We can repeat this procedure for several fractions of “”TRUE” pathogenic genes (10-80% in 
increments of 5%) and determine the range of possible MAPS scores given a particular 
proportion of genes contributing true pLOF variants. Since the baseline estimate for uORF 
variants is higher than that for synonymous coding variants, we adjust these MAPS scores by 
adding the baseline estimate for uORF variants to all simulated MAPS scores. We then plot the 




Figure 3.24: Relationship between the fraction of true LOF variants in ClinVar pathogenic 
genes and MAPS scores adjusted for uORF-synonymous variants baseline. Black line 
represents MAPS scores for UTC and stop-strengthening variants combined in all uORFs. 
Orange points represent the mean of MAPS scores over 10,000 bootstraps. Orange band 
represents 90% confidence interval of 10,000 bootstraps MAPS scores at each simulated 
proportion of genes contributing true pLOF variants. 
 
We fit a simple regression model to these simulated MAPS scores as a function of the proportion 
of genes contributing LOF variants, and use the fitted model to determine the proportion of LOF 
features corresponding to the MAPS score for uORF-UTC and stop-strengthening variants. This 
corresponds to the proportion of uORFs contributing UTC or stop-strengthening variants with 
loss-of-function consequences capable of causing pathogenicity in humans. Solving this linear 
equation gives an estimate of the proportion of uORFs where UTC or stop-strengthening variants 
have comparable consequences as LOF protein coding variants in ClinVar pathogenic genes. 
This gives us the estimate of 24.15354%. We fit separate lines to the 5% and 95% bootstrapped 
89 
 
MAPS estimates at each proportion to determine the 90% confidence interval for this estimate 
(21.35285 - 27.33626). 
To derive an estimate of the proportion of uORFs under similar constraint to maintain amino acid 
identity as protein-coding regions of the genome, we repeat the above procedure substituting 
missense variants in all protein coding genes for pLOF variants in ClinVar disease-associated 
genes. This procedure gives us an estimate of 9.916032% (5.216744 - 14.69604). 
 
 
Figure 3.25: Relationship between the fraction of true missense variants in all protein-
coding genes and MAPS scores adjusted for uORF-synonymous variants baseline. Black 
line represents MAPS scores for predicted missense variants for all uORFs. Red points represent 
the mean of MAPS scores over 10,000 bootstraps. Red lines above and below points represent a 




CHAPTER 4: TRANSLATING REGULATORY INSIGHTS INTO THERAPIES 
 
4.1: G-quadruplexes and upstream open reading frames in UTRs 
Much of the human genome is noncoding, but knowledge of how and when genetic variation can 
impact biology and disease has been primarily limited to coding sequences. Interpreting genetic 
variation in noncoding DNA remains challenging because the universe of functional noncoding 
elements in the human genome remains incompletely mapped and because the potential impact 
of variants affecting known noncoding regulatory elements is difficult to predict. Here, we have 
adopted an integrated omics approach towards addressing these dual challenges: first, by 
examining the genetic and genomic evidence that putative G-quadruplex forming sequences in 
UTRs of mRNAs are functional, and second by elucidating new patterns of functional variation 
affecting translated upstream open reading frames. For putative G-quadruplex forming 
sequences in UTRs, we have shown that central guanines in the canonical G-quadruplex motif 
are significantly depleted of genetic variation in concordance with their importance for facilitating 
stable secondary structure formation. We further find that these sequences are enriched for cis-
eQTLs annotated in GTEx, and overrepresented among RNA-protein binding interactions 
mapped by ENCODE. Taken together, this evidence suggests that UTR G-quadruplexes are 
functional noncoding elements in UTRs. 
Although these studies imply that G4 forming sequences in UTRs are constrained by selection, 
dissecting the precise functional importance of these sequences will be an important step to 
understand their roles more clearly in gene regulation. Our finding that both 5’ and 3’UTR G4 
sequences are enriched for cis-eQTLs implies that these sequences are broadly capable of 
influencing mRNA abundance. In particular, the enrichment for cis-eQTLs in 3’UTR protein 
suggests that G4s in 3’UTRs are involved in mediating mRNA stability [32], and that this is 
accomplished by facilitating RNA-protein binding interactions. More generally, the observed 
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enrichment for RNA protein binding interactions over both 5’ and 3’ UTR G4s implies that the 
capacity for these secondary structures to bind proteins is central to their functionality. 
Whether some subsets of G4 binding proteins bind differentially to folded versus unfolded G4 
secondary structures remains an interesting question for further investigation. Indeed, 
subsequent studies have replicated our findings that helicase RNA-binding proteins including 
DDX6 tend to bind G-rich sequences capable of forming G4 structures [179], suggesting that 
dynamic folding and unfolding UTR G4s plays a role in regulation. G4 folding could possibly mask 
other regulatory protein binding sites within mRNAs, or create a new substrate for protein binding, 
depending on cell state. Our finding that many UTR sequences with potential G4 structures tend 
to be overrepresented among genes involved in cellular stress response pathways further implies 
that differential G4 binding interactions may be involved in post-transcriptional responses to 
cellular stress. Future targeted functional studies should explore this possibility further. 
We have additionally examined patterns of selective pressure in non-canonical open reading 
frames mapped through ribosome profiling experiments. Our analysis of allele frequencies in 
gnomAD identified uORF stop-introducing and stop-strengthening variants as categories of 
variation in the 5’UTR that exhibit a strong signature of negative selection, comparable to that of 
missense mutations in protein-coding regions of the genome. We further demonstrate that certain 
uORF stop-strengthening and stop-introducing variants associated with human disease 
phenotypes in two EHR-based biobanks can decrease downstream protein expression in reporter 
gene assays. Together, these data demonstrate that variants introducing new stop codons or 
strengthening existing stop codons in uORFs can impact protein expression and imply that they 
may contribute to human disease.  
Previous studies of translational regulation by uORFs have revealed that several additional 
factors, including the strength of a uORF start codon [180], intercistronic distance between the 
uORF stop codon and downstream coding gene [181,182], and potential secondary structures in 
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the 5’UTR can impact translational regulation by uORFs [183,184]. Although these factors were 
not addressed in the current study, they are likely to influence the ability for uORF stop-
introducing or stop-strengthening variants to decrease downstream protein expression. Notably, 
mutagenesis studies have reported that shortening repressive uORFs significantly may result in 
increased expression of downstream proteins [181]. This raises the possibility that some uORF 
stop-introducing variants can confer gain-of-function rather than loss-of-function depending on the 
length of the uORF they interrupt, the specific uORF that is affected, and the amount by which the 
uORF is shortened. In the scanning model of translation initiation, uORF-mediated translational 
repression occurs by preventing ribosomes from reacquiring the necessary translation initiation 
factors in time to begin translation at the downstream CDS. Thus, uORF stop-introducing variants 
may sufficiently lengthen the intercistronic distance between uORF and CDS to release 
downstream coding sequences from uORF-mediated translational repression. Further 
characterizing the precise relationship between intercistronic distance and uORF repressiveness 
will help improve our ability to accurately predict when uORF stop-introducing variants can 
increase protein expression. 
The observed allele frequencies of variants affecting translated uORFs also suggests that these 
regulatory elements largely act at the level of translation rather than through encoding functional 
micropeptides. In support of this interpretation, we do not observe widespread evidence that 
amino acid encoding is constrained in most non-canonical ORFs, but we do observe that uORF 
translation initiation in 5’UTRs is maintained by selection. While there has been growing interest 
in the possibility functional micropeptides are widely encoded in ncORFs throughout the genome, 
the absence of significant selection to maintain amino acid encoding in ncORFs more broadly 
suggests that the functionality of micropeptides is either not associated with their amino acid 
encoding, or that perhaps that the fraction of functional micropeptides is much smaller than 
implied through ribosome profiling studies. Indeed, as translation in 5’UTRs has long been 
observed to have regulatory functions, it is possible that widespread translation in ncORFs may 
93 
 
also have regulatory rather than peptide-encoding roles in biology. Nevertheless, it remains 
possible that patterns of selection in ncORF encoded micropeptides do not reflect similar 
selective forces as those acting in canonical protein coding regions of the genome. In this 
scenario the function of ncORF micropeptides may alternatively depend on their length, or 
perhaps the presence of a few key amino acids in their sequence. 
 
4.2: From regulation to therapy 
Together, our studies help expand the understanding of regulatory elements in UTRs, and the 
interpretation of genetic variation in 5’ and 3’ UTRs – core components of all protein-coding 
messenger RNAs. As databases of human genetic variation grow larger, so too will the resolution 
by which we can observe and understand patterns of functional genetic variation in noncoding 
DNA. Further work establishing detailed maps of functional noncoding RNA regulatory elements 
will help inform the future development of new medicines which manipulate these regulatory 
elements for therapy. Indeed, drugging RNAs has received growing interest as a therapeutic 
mechanism in recent years [185]. The molecular tools of RNA manipulation – including small 
interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) – have existed for decades, 
however strategies for modulating protein activity or direct genome editing have traditionally 
received greater attention for therapeutic development. Compared to small molecules, 
oligonucleotides do not widely distribute throughout the body with the same efficiency, thus 
developing improved targeted drug delivery strategies is critical to realizing the promise of 
oligonucleotide therapies.  
Nevertheless, interest in RNA targeting drugs has grown in recent years as advances in our 
understanding of RNA regulation and disease has improved. Early oligonucleotide-based 
therapies were developed for pharmacologically convenient tissues in the human body, beginning 
with the eye. Approved by the FDA over 20 years ago as a therapy for cytomegalovirus retinitis, 
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the first antisense oligonucleotide to find use in humans, Fomivirsen, acted through blocking 
translation of viral mRNAs and was delivered by intravitreal injection [187]. As advances in 
oligonucleotide chemistry conferred greater resistance to degradation and improved 
biodistribution, other routes of administration and mechanisms of action became feasible [186]. 
Subsequent RNA-based therapies have focused on modulating alternative splicing, or inducing 
RNA degradation relying on intravenous administration for muscle targeting or intrathecal delivery 
for targeting neurons [185]. Despite these advances, oligonucleotide delivery remains much less 
efficient than for small molecules, and devising improved methods for targeted delivery remains a 
key bottleneck to the translational application of oligonucleotides for therapy [188]. 
Informed by our growing appreciation for the diversity of RNA regulatory mechanisms, there is 
now increasing interest in new strategies for changing protein expression at the RNA level. 
Indeed, approaches for targeting G-quadruplex elements and uORFs to modulate protein 
expression have been proposed previously in the literature [189–191], and several preclinical 
studies have been published with promising results across a number of human disease 
contexts[192–196]. As catalogues of RNA regulatory elements encoded in the transcriptome 
expand, so too will the possibilities of therapeutic manipulation.  
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APPENDIX A: Methods for Integrative analysis reveals RNA G-quadruplexes in 
UTRs are selectively constrained and enriched for functional associations 
Identification of UTR G-quadruplex Sequences 
Annotated UTR sequences and genomic coordinates were downloaded using biomaRt[189,190] 
for Ensembl Transcript Database version 75 for all protein-coding transcripts. Putative G-
quadruplex forming sequences (pG4) were identified using this set of annotated UTRs by 
performing a pattern-matching text search to identify regions of UTRs matching the canonical G-
quadruplex pattern as a regular expression: (G:3+)-{N:1-7}(3)-(G:3+). Genomic coordinates for 
pG4 sequences within UTRs were obtained using a custom python script, and cross-referenced 
with annotated protein-coding regions of the genome from the Ensembl Transcript Database to 
remove overlaps between annotated UTRs and coding sequences using human genome hg19 
coordinates. The identified set of 5’ and 3’ pG4 sequences, and corresponding genomic 
coordinates were used for all downstream analysis. This approach yielded a total of 5235 protein-
coding genes harboring a UTR pG4 sequence, with 2967 genes having a 5’UTR pG4, and 2835 
genes having a 3’UTR pG4. Of the 5235 genes with either a 5’ or 3’ UTR pG4, 567 have both. 
A second set of pG4 sequences with evidence of secondary structure formation was defined by 
overlapping pG4 motifs identified transcriptome-wide with published in vitro rG4-seq annotations 
by using the K+PDS conditions [63]. Only the subset of rG4-seq G4s matching the canonical pG4 
motif were used in this analysis. For the set of rG4 sequences, we find 243 protein-coding genes 
encoding a 5’UTR rG4, and 803 genes encoding a 3’UTR rG4. Of these rG4 genes, 16 have 5’ 





Variants from gnomAD release 2.2.1 were obtained from (URL here: 
https://gnomad.broadinstitute.org/downloads) and filtered to exclude those marked with 
segmental duplication, low complexity regions (LCR), and decoy flags, in addition to those 
variants whose True Positive probability as determined by a random forest model trained in 
gnomAD did not exceed 40% [44]. As an additional requirement, only those variants where the 
total observed allele number was at least 80% of the maximum number of sequenced alleles was 
considered to control for differences in sequencing depth in the gnomAD WGS dataset. The 
remaining set of high-confidence variants was overlapped with genomic coordinates for UTR 
pG4, non-pG4, and CDS regions, using bedtools2 (version 2.27.1) intersect with the -u and -b 
flags.  
The transcript constraint-table from gnomAD release 2.2.1 (URL 
https://gnomad.broadinstitute.org/downloads) was used to randomly select a matching set of 
transcript-level constraint-matched non-pG4 UTR sequences based on the gnomAD observed / 
expected metric for the 5’ UTR and 3’ UTR separately. Specifically, transcript constraint was 
matched between pG4 and non-pG4 forming sequences using the observed versus expected 
ratio of loss of function variants metric (LOEUF) provided for each transcript by gnomAD. 
The fraction of variants per sequenced allele across UTR regions were computed as the fraction 
of the observed allele count versus observed allele number. The distribution of frequencies for 
variants mapping to each UTR region was extracted from the gnomAD summary variant call files 
directly. P-values for difference between the expected number of variants per sequenced allele 
across genomic regions were calculated using a two-sided Fisher exact test. Only variants that 
did not overlap annotated coding regions of the transcriptome were compared to ensure that 
UTRs overlapping coding regions of other transcript isoforms were excluded. All statistical tests 




For positional constraint analysis, we applied the mutability-adjusted proportion of singletons 
(MAPS) metric [37] for each nucleotide position across all trinucleotide G-tracts with G4-forming 
capacity, as defined by our bioinformatic analysis. We developed a MAPS model using custom 
code based on a previously published MAPS model (https://github.com/pjshort/dddMAPS) with 
the addition of adjusting for methylation levels at variant positions. We divide variants by median 
estimated methylation levels across 37 tissues at CpG sites into None/Low (<0.2), Intermediate 
(0.2-0.6), or High (0.6<) bins for which separate methylation-adjusted mutation rates were 
available. Our model was trained by regressing the observed proportion of singleton synonymous 
variants for each trinucleotide context within protein-coding regions of the genome on mutation 
rates for each trinucleotide context (methylation-adjustment was performed only at CpG 
dinucleotides) derived from intergenic noncoding regions of the genome [137]; [44]. All variants 
used in this analysis, including synonymous variants used for training the model, were subject to 
the same filtering requirements as used in the analysis of allele frequencies (random forest True 
Positive probability exceeding 40%, and total observed allele number was at least 80% of the 
maximum number of sequenced alleles). To control for ambiguity regarding which specific 
guanines within each G-tract are involved in pG4 formation for G-tracts having more than 3 
guanines, we considered only variants within trinucleotide G-tracts. MAPS values were also 
determined for the set of variants with a VEP consequence of missense, or those variants 
predicted to cause a loss of function (pLoF) in gnomAD to provide context for the different 
degrees of purifying selection acting over a set of variants. pLoF variants were defined as those 
annotated with Ensembl predictions for having a high impact and includes transcript_ablation, 
splice_acceptor_variant, splice_donor_variant, stop_gained, frameshift_variant, stop_lost, and 
start_lost terms. In our assessment of positional constraint within the meta-pG4 sequence 
consisting of only trinucleotide G-tracts, we calculated MAPS for four categories of pG4 variants: 
1) all genes, 2) genes with at least one transcript falling in the upper one-third of transcripts that 
are most intolerant to loss of function mutations (as determined by the gnomAD o/e metric), 3) 
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alternative pG4 genes, and 4) alternative pG4 disease-associated genes extracted from ClinVar 
database (April, 2019 release). Permutation P-values were obtained by performing 10,000 
bootstraps for each set of pG4 variants in gnomAD with replacement to produce a distribution of 
MAPS score for each variant context; and then comparing these distributions to a matched set of 
resampled MAPS scores using either all UTR variants, or position-matched non-pG4 GGG/CCC 
trinucleotide variants to determine the proportion of bootstrapped samples whose MAPS score of 
pG4 regions exceeded the matched non-pG4 variant set. 
Posterior substitution probabilities for noncoding regions of the genome based on local 
heptameric sequence contexts were obtained from a published model [75] based on the Phase 1 
release of the 1000 Genomes Project. Cumulative substitution probabilities for each of the 
possible mutations within a heptamer context (e.g. A→C, A→T, A→G) were calculated by 
summing over all nucleotide substitution probabilities for a given heptamer context. To produce a 
null distribution of observed / expected number of substitutions for non-pG4 regions of the UTR, 
we randomly sampled 5000, 25 nucleotide UTR regions from constraint-matched transcripts, 
10,000 times to generate a null distribution. Specifically, constraint-matched non-pG4 transcripts 
were divided into heptamers using a sliding window across the entire region, and substitution 
probabilities based on heptameric context alone was summed for each nucleotide position of 
each region to estimate the expected substitution frequency across each region of interest. The 
number of expected substitutions as derived from the heptamer substitution model for a given 
region was compared to observed substitutions for the European subpopulation within the Phase 
1 of the 1000 Genomes Release. We performed comparisons across UTR pG4 G-tracts, pG4 
non-G-tract Gap sequences, and constraint-matched non-pG4 UTRs for all pG4s, and the subset 
of rG4-seq supported pG4 motifs. Because the model does not adjust for methylation at CpG 
dinucleotides, all CpG dinucleotide positions within UTRs were removed from consideration. 
Statistical significance was determined by randomly sampling a set of genomic positions from 
each region of interest with replacement, matching the original combined size of each region, 
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over 10,000 iterations to produce a distribution of observed / expected ratios for each region of 
interest. P-values for each region (pG4, rG4, gap sequences) were calculated as the proportion of 
the observed / expected ratios obtained from the above bootstrapping procedure that were less 
than a matched set of observed / expected ratios using all 5’ and 3’UTR genomic positions 
obtained by the same procedure.  
 
pG4 Isoform Expression Across Tissues in GTEx 
The median expression of each annotated RNA transcript (as measured in units of TPMs) in each 
tissue context was downloaded from GTEx v7. Median TPMs for each transcript were extracted 
for all pG4- or non-pG4 containing transcript for each pG4 gene, the highest expressed pG4 or 
non-pG4 isoform was selected, and a threshold of 1 TPM was used to determine expression 
within a specific tissue context. pG4 transcripts were deemed constitutive if only one of the pG4, 
or none of the non-pG4 transcripts exceeded this threshold, and labeled alternative if both the 
pG4, and non-pG4 transcripts exceeded this threshold. Significance of the distribution of 
alternative versus constitutive UTR pG4-encoding genes was assessed by randomly assigning 
pG4 and non-pG4 transcripts each gene, maintaining the number of transcript isoforms encoded 
by each gene constant with the condition that each gene should contain at least 1 pG4-encoding 
transcript. The distribution of the ratio of alternative to constitutive pG4 genes from the randomly 
distributed pG4 transcripts was then computed over 10,000 iterations to obtain a P-value for the 
true ratio of alternative to constitutive UTR pG4 encoding genes. 
 
cis-eQTL and protein-binding enrichment 
Significant variant-gene pairs were obtained from GTEx release version 7 (URL: 
https://gtexportal.org/home/datasets) constituting the set of nominally significant cis-eQTLs. Lead 
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cis-eQTL variants for each gene were defined as the variant with the lowest P-value for each 
gene, from the set of all significant variants in each tissue context separately. The set of lead and 
nominally significant variants was overlapped with UTR pG4 and non-pG4 regions of the UTR, 
and the number of significant cis-eQTL variants per region was compared to the number of non-
significant tested SNPs occupying the same region to determine the proportion of cis-eQTLs 
compared to non-cis-eQTL SNPs. UTRs with cis-eQTLs not associated with changing the 
expression of the parent gene were excluded this analysis. Enrichment of cis-eQTLs was 
computed using a two-sided Fisher Exact Test. The set of causal eQTL candidates were obtained 
directly from the supplemental material of Brown et. al [80], and enrichment statistics were 
computed using GTEx v6p tested SNPs instead of v7 to match the data used in that study. 
The direction bias of nominally significant cis-eQTLs within UTR pG4 G-tracts versus non-G-tract 
variants was computed by binarizing the normalized effect size pre-computed for each QTL by 
GTEx, and comparing the proportions of QTLs in each feature with either a positive effect, or 
negative effect on gene expression for each possible cis-eQTL annotation across all tissue 
contexts combined. Statistical significance was determined by a two-sided Fisher Exact Test. 
High-confidence protein-binding sites were obtained from ENCODE CLIP-seq summaries and 
only peaks called with an Irreproducible Discovery Rate = 1000 were used for downstream 
enrichment analyses as determined by ENCODE [82]. Overlapping binding sites for multiple 
proteins were collapsed into a single protein-binding site, and the density of unique binding sites 
overlapping UTR pG4 regions compared to non-pG4 regions of the UTR was compared by 
dividing the number of CLIP-seq peaks overlapping each feature by the total number of 





Proteins whose binding sites are enriched for pG4 overlaps were computed using a 
hypergeometric test, by comparing the proportion of set of pG4 containing versus non-pG4 
binding sites for a given RBP compared against the background proportion of of all UTR CLIP-
seq peaks containing a pG4 sequence. The significance of pairwise overlaps between protein-
gene targets was also computed using a hypergeometric test to assess the degree that one 
protein’s pG4 binding genes were also targets for another protein.  
 
Gene Expression with RBP Knockdown in ENCODE 
Processed differential gene expression tables for K562 and HepG2 were obtained directly from 
ENCODE (https://www.encodeproject.org/) for each of the pG4-enriched binding proteins and 
their respective knockdown experiments. For each experiment, a gene was considered 
differentially expressed at an FDR threshold of < 0.05. Genes from ENCODE differential 
expression tables were annotated as either a pG4 gene or non-pG4 gene on the basis of whether 
they encoded for a transcript isoform possessing a UTR pG4 sequence in either the 5’UTR or 
3’UTR. The odds ratio for being significantly differentially expressed was calculated by comparing 
the ratio of pG4 to non-pG4 genes reaching statistical significance for differential expression 
between shRNA knockdown of the RBP, and the control for each protein separately. Statistical 
significance was determined by Fisher’s Exact Test and FDR was controlled at 0.001 by applying 
the Benjimini-Hochberg procedure to the resultant P-values for each cell line. The direction of 
effect on pG4 gene expression for protein knockdown to cause an increase or decrease in pG4 
gene expression was determined by taking the median value for log2-fold change in expression 
for all pG4-containing genes measured in a given experiment. 
 
Variants in ClinVar and the NIH-GWAS Catalogue 
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The April 2019 release of ClinVar was obtained from ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/. Using 
these variant annotations, we identified a subset of disease associated genes as any gene with at 
least one variant having a Pathogenic or Likely Pathogenic annotation. These genes were used 
to subset the ClinVar database and all variants spanning 40 nucleotides or less were overlapped 
with UTR regions to assess for enrichment in pG4 sequences. Insertions or deletions spanning 
greater than 40 nucleotides were not considered in this analysis, nor were any variants with an 
annotation of Benign or likely benign in Clinvar. The number of variants across each region was 
then divided by the total number of bases in each respective region to estimate of the density of 
variation in a given region. The odds ratios for the number of single nucleotide variants compared 
to the number of bases in a given region were then compared using a two-sided Fisher Exact 
Test. 
For identification of GWAS-implicated SNPs affecting annotated UTR pG4 sequences, publicly 
available phenotype-associated SNPs from were obtained from the NIH-EBI GWAS Catalogue. 
Genomic coordinates for GWAS SNPs were converted from hg38 to hg19 coordinates using the 
NCBI Genome Remapping Service (https://www.ncbi.nlm.nih.gov/genome/tools/remap). This set 
of lead GWAS SNPs was used to identify nearby linked SNPs in high LD using the Linkage 
Disequilibrium Calculator tool from the Ensembl GRCh37 website using a 50KB window 
surrounding each lead GWAS SNP and selecting the set of SNPs with r2 > 0.85 using the GBR 
population of the 1000 Genomes Project.  
 
Allele-specific expression for GWAS-variants 
RNA-seq libraries were trimmed using TrimGalore [191]. Reads were aligned to the GRCh37 
human genome using STAR (version 2.7.0c) with the WASP-filtering option, and matched whole-
genome sequencing variant files obtained from GTEx for Skeletal Muscle, Thyroid, Fibroblast, 
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Esophagus, and Tibial Nerve tissue samples. Reads that did not pass WASP-filtering were 
removed from the resulting aligned bam files. PCR duplicates were removed using the python 
script remove_duplicates.py included in the WASP version 0.3.3 pipeline 
(https://github.com/bmvdgeijn/WASP). Read counts matching the reference and alternate alleles 
in the resultant WASP-filtered bam files were compiled using bcftools mpileup across UTR pG4 
variants. A beta-binomial model was fitted using the R VGAM package [192] for each variant 
across all heterozygous samples identified using matched whole-genome sequencing from GTEx 
to estimate the ratio of reference reads to alternate reads. Estimates of statistical significance 
were obtained by using a likelihood ratio test comparing the log-likelihood of the observed count 
distribution for each variant using the beta-binomial estimate for ρ versus the null hypothesis of 
no bias (ρ = 0.5).  
 
Code Availability 
All analysis scripts used to generate the primary results and figures reported in this study are 
publicly available from: https://bitbucket.org/biociphers/g4-paper-2019/src/master/. 
 
Data Availability 
Pre-processed data, and instructions for how to access public data resources used in this study 
that can be used to regenerate the primary figures of this analysis have been uploaded to 
https://bitbucket.org/biociphers/g4-paper-2019/src/master/. A subset of the processed publicly 
available data underlying Figs 3, 4, and 5 are included in this repository, with associated 
instructions on how to access other data as required to regenerate these figures where 
necessary. This repository also contains a link to a Source Data file which contains raw data 
underlying Figs 1b-d, 3a, b, 4a-d, 5a, c, d, and Supplementary Figs 5 and 7. Genetic variation 
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data from The Genome Aggregation Database version 2 release are available from: 
https://gnomad.broadinstitute.org/downloads. Gene expression and cis-eQTL mapping data from 
the Genotype Tissue Expression Project version 7 release are available from the GTEx Portal 
website: https://gtexportal.org/home/. RNA-seq data used for allelic imbalance analysis are 
available from dbGaP (phs000424.v7.p2 [https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000424.v7.p2]). RNA-protein binding interaction data can be retrieved 
from the ENCODE Consortium: https://www.encodeproject.org/. GWAS-associated variation data 
can be accessed from the NIH-EBI GWAS Catalog: https://www.ebi.ac.uk/gwas/. A copy of the 
filtered ClinVar database used to generate Fig. 5a is included in the code repository from April 
2019. The most updated version of disease-associated genetic variant annotations are also 
available from ClinVar: https://www.ncbi.nlm.nih.gov/clinvar/. 
 
Statistics 





APPENDIX B: Methods for Disrupting upstream translation in mRNAs is 
associated with loss-of-function in human disease 
Annotation of translated non-canonical open reading frames 
Non-canonical ORF (ncORF) annotations encompassing 5’UTR ORFs (uORFs), 3’UTR ORFs 
(dORFs), long-noncoding RNA ORFs (lncRNA) and pseudogene ORFs were retrieved from 
Supplementary File 1 from Ji et al. [121]. These ncORFs were mapped by ribosome-profiling in 
human BJ fibroblasts and MCF10A breast epithelial cells using the RibORF algorithm. Using the 
final set of genomic coordinates for ncORFs identified in this study, we converted these 
coordinates to match hg38 annotations using the UCSC LiftOver executable 
(https://genome.ucsc.edu/cgi-bin/hgLiftOver). Out of 10,007 distinct non-canonical uORFs 
mapped in the original study, 27 whose length changed after conversion (N = 5 uORFs, 4 dORFs, 
16 lncRNA ORFs, 2 pseudogenes) were excluded from subsequent analyses. Each Refseq 
mRNA ID for each ORF-associated RNA transcript was annotated to its associated Ensembl 
transcript ID using the BioMart database v86 annotations. The first three nucleotides of each ORF 
were used as start codons for downstream analyses. The final three nucleotides of each ORF 
were used as stop codons for downstream analyses. 5’ and 3’ UTR definitions used in this study 
are derived from the Ensembl v86 annotations. 
 
Quality filtering and annotation of variants from gnomAD version 3 
Variants from gnomAD 3 release were downloaded from the gnomAD browser website 
(https://gnomad.broadinstitute.org/downloads). A set of high-confidence variants were obtained 
by removing those failing the Filter column (Filter != PASS) from the gnomAD version 3 vcf files 
using bcftools (version 1.9), and those falling in low complexity regions (lcr != 1). This set of 
variants was used for all downstream analyses. We additionally removed variants where the total 
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observed allele number was at less than 80% of the maximum number of sequenced alleles to 
control for differences in sequencing depth in the gnomAD WGS dataset. The remaining set of 
high-confidence variants was overlapped with genomic coordinates for annotated ncORFs, 5’UTR 
sequences, and annotated protein-coding sequences using bedtools (version 2.27.1) intersect 
with the -u and -b flags. The predicted consequence of each variant was obtained using the 
Ensembl Variant Effect Predictor (VEP, version 98.2) based on hg38 gene models obtained from 
Ensembl. VEP consequences were further filtered to only include the predicted consequence for 
the canonical Ensembl transcript as determined in [136].  
 
Positional constraint analysis using variants from gnomAD 
For the positional constraint analysis we applied the MAPS metric to each variant set. We 
developed a MAPS model following previous methods [136]. The set of synonymous protein-
coding variants are used as a baseline measurement for neutral selection, and the proportion of 
singletons in a variant class are adjusted for differences in mutation rates due to local sequence 
context [37,136]. We trained our model by regressing the observed proportion of singleton-
synonymous variants for each trinucleotide context within protein-coding regions of the genome 
using previously published context-dependent mutation rates derived from intergenic noncoding 
regions of the genome [136]. Since negative selection prevents deleterious mutations from 
becoming common in human populations, more deleterious mutations - including those disrupting 
essential splice sites or introducing premature termination codons - are also more enriched for 
singletons compared to neutral variants. 
MAPS scores for a given set of variants are calculated as described previously [37,135,136]. 
Briefly, for a given set of variants, we use the MAPS model to determine the expected number of 
singletons that should be observed, based on the transformed mutation rates which account for 
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trinucleotide context and methylation levels. To calculate the MAPS score, we take the observed 
number of singletons for this set of variants, and subtract the expected number of singletons 
calculated using the MAPS model. We then divide this value by the number of variants total to 
obtain the proportion of singleton variants adjusted for mutation context. 
To estimate of MAPS scores for missense-causing mutations in canonical protein-coding 
sequences within the genome, we selected the subset of SNVs in gnomAD with an annotated 
VEP consequence of missense, and removed SNVs from this set of variants if they had additional 
VEP annotations that could be considered predicted loss-of-function (pLoF). The set of variants 
used to calculate MAPS scores for pLoF variants relied on aggregating variants with a VEP 
annotation of transcript_ablation, splice_acceptor_variant, splice_donor_variant, stop_gained, 
frameshift_variant, stop_lost, and start_lost terms. The set of synonymous variants used to train 
the MAPS model was filtered to remove variants with any of the previous predicted high impact 
annotations, and those with a possible missense consequence.  
We computed MAPS scores for each set of variants based on uORF annotations, or 5’UTR 
annotations from Gencode (GRCh38.p13; 
https://www.gencodegenes.org/human/release_32.html). Using the set of filtered variants we 
matched them to uORF positions annotated by their relative position within the uORF reading 
frame, strand, and codon. We determined how the mutation affected the codon within the 
translated uORF sequence, and annotated each variant with its consequence on the encoded 
amino acid. We used these annotations to select variants that could introduce new stop codons 
(UTC-introducing variants) and those that strengthened existing stop codons within uORFs. For 
UAA-introducing variants we selected any variant that produced an in-frame UAA stop codon. For 
each set of stop-introducing or stop-strengthening variants, we selected a set of uORF variants 
matching the underlying trinucleotide context of each experimental set of variants. MAPS scores 
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for these variant sets were computed and confidence intervals were determined by resampling 
from each variant set with replacement over 10,000 iterations.  
For codon optimality analysis, we used the set of codon stability coefficients (CSC) scores 
derived from SLAM-seq in 562 cells obtained from https://doi.org/10.7554/eLife.45396.006 [153]. 
Optimality decreasing variants were defined as any variant which decreased the CSC score for 
the encoded codon, and optimality increasing variants were defined as any variant which 
increased the CSC score for the encoded codon. 
Confidence intervals for MAPS scores were calculated using bootstrapping as described [135]. 
For each set of n variants used to compute a MAPS score, we select n variants randomly with 
replacement and recalculate MAPS scores. This is repeated over 10,000 permutations and the 
5th and 95th percentiles of the MAPS scores distribution are used as confidence intervals. P-
values for differences in MAPS scores were determined by calculating the proportion of 
bootstrapped MAPS scores from an experimental group of variants that were larger than those 
from the control group [135].  
 
Determining the distribution of stop codons used by upstream open reading frames 
Stop codons from each uORF were extracted based on genomic coordinates and the uORF 
reading frame. Confidence intervals were determined by sampling with replacement from the set 
of uORF stop codons over 10,000 iterations. For 5’UTR sequences, all stop-codon matching 
trinucleotides (UGA, UAG, UAA) were extracted from annotated canonical 5’UTR sequences of 
protein-coding genes in the BioMart Ensembl database (version 86). The set of canonical 
transcripts annotated in the gnomAD flagship release paper were used to define 5’UTR 
sequences for this analysis [136]. For each iteration, one stop codon was randomly selected from 
each 5’UTR and the proportion of UGA, UAG, and UAA trinucleotides selected from all 5’UTR 
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sequences were calculated. This procedure was repeated 10,000 times to form a distribution of 
TGA, TAG, and UAA trinucleotides in all 5’UTR sequences. This procedure was also repeated for 
uORF-matched UTR sequence segments that did not overlap known translated uORFs. P-values 
for the depletion of UAA stop codons used in translated uORFs were calculated by determining 
the number of bootstrap iterations where the frequency of UAA codons from uORFs was higher 
compared to non-uORF sequences. P-values for enrichment of UGA and UAG sequences were 
calculated by determining the fraction of sampled iterations where fewer UGA and UAG 
sequences were selected from uORF stop codons compared to all 5’UTRs and uORF-matched 
5’UTR sequences respectively. 
 
Assessing variant conservation using genome-wide phyloP scores 
PhyloP scores for each base were downloaded from the UCSC genome browser 
(http://hgdownload.cse.ucsc.edu/goldenpath/hg38/phyloP100way/). 1-indexed bigwig files were 
converted to bed file format using the wig2bed tool from bedops (version 2.4.36; 
https://bedops.readthedocs.io/en/latest/index.html). These base-level annotations were matched 
to each uORF base and used to determine the proportion of bases that were significantly 
conserved (proportion of bases with phyloP score > 2). Possible inframe stop-codon creating 
positions were identified based on mapped reading frames for each uORF. These sites were 
extracted and further categorized by whether or not a mutation could create a UGA, UAG, or UAA 
stop codon. Some positions could be mutated to either a UGA, UAG or UAA codon and these 
were considered separately from potential UGA, UAG or UAA-creating positions. We have 
included all potential stop-introducing positions in Suppl. File 1. As a control we used phyloP 
scores for genomic positions with the potential to create non-uORF UGA, UAG, or UAA 




Start-disrupting genomic positions were annotated as those mutating the second or third position 
in the first codon of each translated uORF. Conservation based on phyloP scores were assessed 
for start-disrupting positions similar to potential stop-introducing positions. As a control we 
compared phyloP scores for uORF start-disrupting positions to out-of-frame start-disrupting 
positions within annotated uORFs, and a set of NTG start-disrupting variants that were not part of 
translated uORFs but matched by distance to the CDS as determined by 10-bp windows. 
P-values were determined by sampling with replacement from each set of variants 10,000 times 
and re-calculating the proportion of significantly conserved bases (phyloP score > 2). The 
distribution of the fraction of conserved base positions were then compared against different sets 
of variants, and the P-value was defined as the fraction of samples where one group was higher 
than the other. 
 
Setting and study participants 
All individuals who were recruited for the Penn Medicine Biobank (PMBB) are patients of clinical 
practice sites of the University of Pennsylvania Health System. Appropriate consent was obtained 
from each participant regarding storage of biological specimens, genetic sequencing, access to 
all available electronic health record (EHR) data, and permission to recontact for future studies. 
The study was approved by the Institutional Review Board of the University of Pennsylvania and 
complied with the principles set out in the Declaration of Helsinki. Replication analyses were 




This PMBB study dataset included a subset of 11,451 individuals in the PMBB who have 
undergone WES. For each individual, we extracted DNA from stored buffy coats and then 
obtained exome sequences generated by the Regeneron Genetics Center (Tarrytown, NY). 
These sequences were mapped to GRCh37 as previously described [155]. Furthermore, for 
subsequent phenotypic analyses, we removed samples with low exome sequencing coverage 
(i.e. less than 75% of targeted bases achieving 20x coverage), high missingness (i.e. greater than 
5% of targeted bases), high heterozygosity, dissimilar reported and genetically determined sex, 
genetic evidence of sample duplication, and cryptic relatedness (i.e. closer than 3rd degree 
relatives), leading to a total of 10,900 individuals. 
For replication studies in UKB, we interrogated the 32,268 individuals of European ancestry 
(based on UKB’s reported genetic ancestry grouping) with ICD-10 diagnosis codes available 
among the 49,960 individuals who had WES data as generated by the Functional Equivalence 
(FE) pipeline. We focused our replication efforts on 32,268 individuals after removing samples 
with poor genotype quality, individuals closer than 3rd degree relatives, and those with dissimilar 
reported and genetically determined sex. The PLINK files for exome sequencing provided by UKB 
were based on mappings to GRCh38. Access to the UK Biobank for this project was from 
Application 32133.           
 
Variant annotation and selection for association testing 
For both PMBB and UKB, genetic variants were annotated using ANNOVAR [193] as 5’ 
untranslated region (5’ UTR), predicted loss-of-function (pLOF), or missense variants according 
to the NCBI Reference Sequence (RefSeq) database [193,194]. Rare (MAF ≤ 0.1%) pLOF 
variants were defined as frameshift insertions/deletions, gain/loss of stop codon, or disruption of 
canonical splice site dinucleotides. Predicted deleterious rare (MAF ≤ 0.1%) missense variants 
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were defined as those with Rare Exonic Variant Ensemble Learner (REVEL) [195] scores ≥ 0.5. 
pLOF and REVEL-informed missense variants were selected for gene burden testing to validate 
the robustness of significant uORF variants’ corresponding gene-disease associations. 
 
Clinical data collection 
International Classification of Diseases Ninth Revision (ICD-9) and Tenth Revision (ICD-10) 
disease diagnosis codes and procedural billing codes, medications, and clinical imaging and 
laboratory measurements were extracted from the patients’ EHR for PMBB. ICD-10 encounter 
diagnoses were mapped to ICD-9 via the Center for Medicare and Medicaid Services 2017 
General Equivalency Mappings (https://www.cms.gov/Medicare/Coding/ICD10/2017-ICD-10-CM-
and-GEMs.html) and manual curation. Phenotypes for each individual were then determined by 
mapping ICD-9 codes to distinct disease entities (i.e. Phecodes) via Phecode Map 1.2 using the 
R package “PheWAS” [156,196]. Patients were determined to have a certain disease phenotype 
if they had the corresponding ICD diagnosis on two or more dates, while phenotypic controls 
consisted of individuals who never had the ICD code. Individuals with an ICD diagnosis on only 
one date as well as individuals under control exclusion criteria based on PheWAS phenotype 
mapping protocols were not considered in statistical analyses. 
For UKB, we used the provided ICD-10 disease diagnosis codes for replication studies, and 
individuals were determined to have a certain disease phenotype if they had one or more 
encounters for the corresponding ICD diagnosis given the lack of individuals with more than two 
encounters per diagnosis, while phenotypic controls consisted of individuals who never had the 
ICD code. Individuals under control exclusion criteria based on PheWAS phenotype mapping 





A phenome-wide association study (PheWAS) approach was used to determine the phenotypes 
associated with 5’ UTR variants predicted to create new UAA UTCs, or strengthen existing uORF 
stop sites and carried by individuals in PMBB for the discovery experiment [156]. Each disease 
phenotype was tested for association with each uORF variant using a logistic regression model 
adjusted for age, age2, sex, and the first ten principal components (PCs) of genetic ancestry. We 
used an additive genetic model to collapse variants per gene via an extension of the fixed 
threshold approach [197]. Given the high percentage of individuals of African ancestry present in 
the discovery PMBB cohort, association analyses were performed separately in European 
(N=8198) and African (N=2172) genetic ancestries and combined with inverse variance weighted 
meta-analysis. Only 5’ UTR variants with at least five total alternate alleles in PMBB were 
selected for univariate PheWAS analyses in the discovery phase while variants with greater than 
half of the genotypes annotated as missing due to low quality were excluded. This resulted in a 
final set of N=10 variants. Our association analyses considered only disease phenotypes with at 
least 20 cases, leading to the interrogation of 800 total Phecodes. All association analyses were 
completed using R version 3.3.1 (Vienna, Austria). 
We evaluated the robustness of significant uORF-phenotype associations in the same PMBB 
discovery cohort by aggregating pLOF and predicted deleterious missense variants in each 
uORF’s corresponding gene into a ‘gene burden’ for hypothesis-driven association with the 
significant phenotype from discovery. Only gene burdens with at least five total alternate alleles in 
PMBB were selected for replication studies. All gene burden association studies in PMBB were 
based on a logistic regression model adjusted for age, age2, sex, and the first 10 PCs of genetic 
ancestry. 
Additionally, we replicated our findings in UKB for significant uORF associations in the PMBB 
discovery using 1) hypothesis-driven univariate association studies for the same uORF variants 
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and 2) hypothesis-driven gene burden collapsing pLOF and predicted missense variants for the 
corresponding genes. Only uORF variants and gene burdens with at least five total alternate 
alleles in PMBB were selected for replication studies. Association statistics were calculated 
similarly to PMBB, such that each disease phenotype was tested for association with each gene 
burden or single variant using a logistic regression model adjusted for age, age2, sex, and the first 
10 PCs of genetic ancestry. Replication significance was defined using a P-value threshold of 
0.05. All association analyses for PMBB and UK Biobank completed using R version 3.6.1. 
 
Construction of expression vectors 
The test plasmids used a modified pGL4.12[luc2CP] (Promega) vector backbone where the 
control of expression of the Firefly ORF was modified by the addition of an upstream CMV 
promoter. The modified pGL4.12 vector was linearized using Bgl-II and MreI restriction sites. 
Hybrid 5’UTR fragments containing the entire 5’UTR sequence and the first 91 nucleotides of the 
Luc2 Firefly ORF were produced by gBlock synthesis and received from Integrated DNA 
Technologies using sequences in Suppl. Table 3. Test plasmids were constructed by sub-cloning 
these hybrid 5’UTR sequences for PMVK, VPS53, and BCL2L13 into the modified pGL4.12 
vector to preserve the uORF-CDS relationship for each construct. Correct fragment insertion was 
verified for each engineered construct by sanger sequencing. For PMVK and BCL2L13, the entire 
annotated 5’UTR sequence was used. For VPS53, because of a G-rich sequence in the 5’UTR 
upstream of the uORF complicated synthesis of the gene’s entire 5’UTR fragment, we removed 
the first 75 nucleotides of the annotated 5’UTR sequence. Construct assembly was accomplished 
using the NEB Hi-Fi assembly protocol following manufacturer’s instructions. 
 




HEK293T cells were used for conditional expression of reporter genes. For transient 
transfections, HEK293T cells were split 1 day before transfection and seeded in 24-well plates at 
a density of 100,000 cells per well. 2 ug of the test Firefly reporter plasmid was transfected into 
each well using Lipofectamine 3000 following the manufacturer’s protocol using 1.5 uL of 
transfection reagent and 0.5 uL of the P3000 reagent for each well. As a control for transfection 
efficiency, 0.02 ug of the pRL-CMV Renilla Luciferase plasmid (Promega Accession No. 
AF025843) was co-transfected with firefly luciferase plasmids. Biological replicates were obtained 
by transfecting cells from separate passages on separate days using newly prepared reagents. 
All transfections were repeated using the HeLa cell line. Dulbecco’s modified Eagle’s medium 




Luminescence was measured using the Promega Dual-Luciferase Reporter Assay System 
(E1910) following the manufacturer’s protocol. Cells were lysed by adding 100 uL of lysis buffer 
10 uL of each lysate was transferred to a black opaque 96-well plate. The ratio of Firefly to 
Renilla luminescence with a microplate reader by automatic injection of the Luciferase Assay 
Reagent II and Stop & Glo reagents. Biological replicates were obtained by transfecting cells from 
separate passages on separate days using newly prepared reagents. Luminescence 
measurements were compared within each set of transfections and statistical significance was 
determined using a one-sided T-test comparing the firefly to Renilla expression ratio of each test 





All scripts used in this analysis except for those generating PheWAS results and plots can be 
accessed from https://www.bitbucket.org/biociphers/uorf-paper-2020/src 
 
Data Availability 




The set of variants obtained from 
71,702 whole genome 







5’UTR (uORF), 3’UTR (dORF), 
long-noncoding RNA, and 
pseudogene ORFs mapped by 
the RibORF algorithm from 
ribosome-profiling data 
https://doi.org/10.7554/eLife.08890.023  
CSC scores Codon-stability coefficient scores 







Software Version URL 
Python 3.7.3 https://www.python.org/downloads/release/python-373/ 
R 3.6.1 https://cran.r-project.org/bin/windows/base/old/3.6.1/ 
bedtools 2.27.1 https://github.com/arq5x/bedtools2/releases 
bcftools 1.9 http://samtools.github.io/bcftools/bcftools.html 









1. Mirsky AE, Ris H. The desoxyribonucleic acid content of animal cells and its 
evolutionary significance. J Gen Physiol. 1951;34: 451–462. 
2. Consortium IHGS, International Human Genome Sequencing Consortium. Initial 
sequencing and analysis of the human genome. Nature. 2001. pp. 860–921. 
doi:10.1038/35057062 
3. Imanishi T, Itoh T, Suzuki Y, O’Donovan C, Fukuchi S, Koyanagi KO, et al. Integrative 
annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol. 
2004;2: e162. 
4. Clark MD, Hennig S, Herwig R, Clifton SW, Marra MA, Lehrach H, et al. An 
oligonucleotide fingerprint normalized and expressed sequence tag characterized 
zebrafish cDNA library. Genome Res. 2001;11: 1594–1602. 
5. Britten RJ, Davidson EH. Gene Regulation for Higher Cells: A Theory. Science. 1969. 
pp. 349–357. doi:10.1126/science.165.3891.349 
6. International HapMap Consortium. The International HapMap Project. Nature. 2003;426: 
789–796. 
7. Ikegawa S. A short history of the genome-wide association study: where we were and 
where we are going. Genomics Inform. 2012;10: 220–225. 
8. Edwards SL, Beesley J, French JD, Dunning AM. Beyond GWASs: illuminating the dark 
road from association to function. Am J Hum Genet. 2013;93: 779–797. 
9. Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Järvelä I. Identification of a 
variant associated with adult-type hypolactasia. Nat Genet. 2002;30: 233–237. 
10. Lewinsky RH, Jensen TGK, Møller J, Stensballe A, Olsen J, Troelsen JT. T-13910 DNA 
variant associated with lactase persistence interacts with Oct-1 and stimulates lactase 
promoter activity in vitro. Hum Mol Genet. 2005;14: 3945–3953. 
11. Ward LD, Kellis M. Interpreting noncoding genetic variation in complex traits and human 
disease. Nat Biotechnol. 2012;30: 1095–1106. 
12. Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 
2013;152: 1237–1251. 
13. Kleinjan DA, van Heyningen V. Long-range control of gene expression: emerging 
mechanisms and disruption in disease. Am J Hum Genet. 2005;76: 8–32. 
119 
 
14. Zoghbi HY, Beaudet AL. Epigenetics and Human Disease. Cold Spring Harb Perspect 
Biol. 2016;8: a019497. 
15. Orkin SH, Kazazian HH Jr. The mutation and polymorphism of the human beta-globin 
gene and its surrounding DNA. Annu Rev Genet. 1984;18: 131–171. 
16. Van der Ploeg LH, Konings A, Oort M, Roos D, Bernini L, Flavell RA. gamma-beta-
Thalassaemia studies showing that deletion of the gamma- and delta-genes influences 
beta-globin gene expression in man. Nature. 1980;283: 637–642. 
17. Kioussis D, Vanin E, deLange T, Flavell RA, Grosveld FG. Beta-globin gene inactivation 
by DNA translocation in gamma beta-thalassaemia. Nature. 1983;306: 662–666. 
18. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 
2013;45: 580–585. 
19. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across 
human tissues. Science. 2020;369: 1318–1330. 
20. Ye Y, Zhang Z, Liu Y, Diao L, Han L. A Multi-Omics Perspective of Quantitative Trait 
Loci in Precision Medicine. Trends Genet. 2020;36: 318–336. 
21. Cheng J, Maier KC, Avsec Ž, Rus P, Gagneur J. Cis-regulatory elements explain most 
of the mRNA stability variation across genes in yeast. RNA. 2017. pp. 1648–1659. 
doi:10.1261/rna.062224.117 
22. Leppek K, Das R, Barna M. Functional 5’ UTR mRNA structures in eukaryotic 
translation regulation and how to find them. Nat Rev Mol Cell Biol. 2018;19: 158–174. 
23. Hellen CU, Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. 
Genes Dev. 2001;15: 1593–1612. 
24. Kearse MG, Wilusz JE. Non-AUG translation: a new start for protein synthesis in 
eukaryotes. Genes Dev. 2017;31: 1717–1731. 
25. Green KM, Linsalata AE, Todd PK. RAN translation-What makes it run? Brain Res. 
2016;1647: 30–42. 
26. Nguyen L, Cleary JD, Ranum LPW. Repeat-Associated Non-ATG Translation: 
Molecular Mechanisms and Contribution to Neurological Disease. Annu Rev Neurosci. 
2019;42: 227–247. 
27. Barrett LW, Fletcher S, Wilton SD. Regulation of eukaryotic gene expression by the 
untranslated gene regions and other non-coding elements. Cell Mol Life Sci. 2012;69: 
3613–3634. 
28. Gruber AJ, Zavolan M. Alternative cleavage and polyadenylation in health and disease. 
Nat Rev Genet. 2019. doi:10.1038/s41576-019-0145-z 
120 
 
29. Moszyńska A, Gebert M, Collawn JF, Bartoszewski R. SNPs in microRNA target sites 
and their potential role in human disease. Open Biol. 2017;7. doi:10.1098/rsob.170019 
30. Steri M, Laura Idda M, Whalen MB, Orrù V. Genetic variants in mRNA untranslated 
regions. Wiley Interdisciplinary Reviews: RNA. 2018. p. e1474. doi:10.1002/wrna.1474 
31. Sheets MD, Ogg SC, Wickens MP. Point mutations in AAUAAA and the poly (A) 
addition site: effects on the accuracy and efficiency of cleavage and polyadenylation in 
vitro. Nucleic Acids Res. 1990;18: 5799–5805. 
32. Mayr C. What Are 3’ UTRs Doing? Cold Spring Harb Perspect Biol. 2019;11. 
doi:10.1101/cshperspect.a034728 
33. Kimura M, Ohta T. On Some Principles Governing Molecular Evolution. Proceedings of 
the National Academy of Sciences. 1974. pp. 2848–2852. doi:10.1073/pnas.71.7.2848 
34. Kimura M. Evolutionary Rate at the Molecular Level. Nature. 1968. pp. 624–626. 
doi:10.1038/217624a0 
35. Smith JM, Haigh J. The hitch-hiking effect of a favourable gene. Genet Res. 1974;23: 
23–35. 
36. Hermisson J, Pennings PS. Soft sweeps: molecular population genetics of adaptation 
from standing genetic variation. Genetics. 2005;169: 2335–2352. 
37. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of 
protein-coding genetic variation in 60,706 humans. Nature. 2016;536: 285–291. 
38. Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution 
rates on mammalian phylogenies. Genome Res. 2010;20: 110–121. 
39. Lindblad-Toh K, Garber M, Zuk O, Lin MF, Parker BJ, Washietl S, et al. A high-
resolution map of human evolutionary constraint using 29 mammals. Nature. 2011;478: 
476–482. 
40. Chen K, Rajewsky N. Natural selection on human microRNA binding sites inferred from 
SNP data. Nat Genet. 2006;38: 1452–1456. 
41. Savisaar R, Hurst LD. Both Maintenance and Avoidance of RNA-Binding Protein 
Interactions Constrain Coding Sequence Evolution. Mol Biol Evol. 2017;34: 1110–1126. 
42. Chen G, Qiu C, Zhang Q, Liu B, Cui Q. Genome-Wide Analysis of Human SNPs at Long 
Intergenic Noncoding RNAs. Human Mutation. 2013. pp. 338–344. 
doi:10.1002/humu.22239 
43. Zhang H, Shi X, Huang T, Zhao X, Chen W, Gu N, et al. Dynamic landscape and 
evolution of m6A methylation in human. Nucleic Acids Res. 2020;48: 6251–6264. 
121 
 
44. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The 
mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 
2020;581: 434–443. 
45. Zhang S, Samocha KE, Rivas MA, Karczewski KJ, Daly E, Schmandt B, et al. Base-
specific mutational intolerance near splice sites clarifies the role of nonessential splice 
nucleotides. Genome Res. 2018;28: 968–974. 
46. Whiffin N, Karczewski KJ, Zhang X, Chothani S, Smith MJ, Evans DG, et al. 
Characterising the loss-of-function impact of 5’ untranslated region variants in 15,708 
individuals. Nat Commun. 2020;11: 2523. 
47. Tuller T, Zur H. Multiple roles of the coding sequence 5’ end in gene expression 
regulation. Nucleic Acids Res. 2015;43: 13–28. 
48. Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, Gorospe M. HuR recruits let-
7/RISC to repress c-Myc expression. Genes Dev. 2009;23: 1743–1748. 
49. Mayr C. Regulation by 3’-Untranslated Regions. Annu Rev Genet. 2017;51: 171–194. 
50. Kedde M, van Kouwenhove M, Zwart W, Oude Vrielink JAF, Elkon R, Agami R. A 
Pumilio-induced RNA structure switch in p27-3’ UTR controls miR-221 and miR-222 
accessibility. Nat Cell Biol. 2010;12: 1014–1020. 
51. Meijlink F, Curran T, Miller AD, Verma IM. Removal of a 67-base-pair sequence in the 
noncoding region of protooncogene fos converts it to a transforming gene. Proc Natl 
Acad Sci U S A. 1985;82: 4987–4991. 
52. Tushev G, Glock C, Heumüller M, Biever A, Jovanovic M, Schuman EM. Alternative 3’ 
UTRs Modify the Localization, Regulatory Potential, Stability, and Plasticity of mRNAs in 
Neuronal Compartments. Neuron. 2018;98: 495–511.e6. 
53. Ribeiro DM, Prod’homme A, Teixeira A, Zanzoni A, Brun C. The role of 3’UTR-protein 
complexes in the regulation of protein multifunctionality and subcellular localization. 
Nucleic Acids Res. 2020;48: 6491–6502. 
54. Xu L, Peng L, Gu T, Yu D, Yao Y-G. The 3’UTR of human MAVS mRNA contains 
multiple regulatory elements for the control of protein expression and subcellular 
localization. Biochim Biophys Acta Gene Regul Mech. 2019;1862: 47–57. 
55. Spasic A, Assmann SM, Bevilacqua PC, Mathews DH. Modeling RNA secondary 
structure folding ensembles using SHAPE mapping data. Nucleic Acids Res. 2018;46: 
314–323. 
56. Tian S, Das R. RNA structure through multidimensional chemical mapping. Q Rev 
Biophys. 2016;49: e7. 
57. Watters KE, Lucks JB. Mapping RNA Structure In Vitro with SHAPE Chemistry and 
Next-Generation Sequencing (SHAPE-Seq). Methods Mol Biol. 2016;1490: 135–162. 
122 
 
58. Itzkovitz S, Hodis E, Segal E. Overlapping codes within protein-coding sequences. 
Genome Res. 2010;20: 1582–1589. 
59. Goering R, Hudish LI, Guzman BB, Raj N, Bassell GJ, Russ HA, et al. FMRP promotes 
RNA localization to neuronal projections through interactions between its RGG domain 
and G-quadruplex RNA sequences. Elife. 2020;9. doi:10.7554/eLife.52621 
60. Shafer RH, Smirnov I. Biological aspects of DNA/RNA quadruplexes. Biopolymers. 
2000;56: 209–227. 
61. Arora A, Maiti S. Differential biophysical behavior of human telomeric RNA and DNA 
quadruplex. J Phys Chem B. 2009;113: 10515–10520. 
62. Zaccaria F, Fonseca Guerra C. RNA versus DNA G-Quadruplex: The Origin of 
Increased Stability. Chemistry. 2018;24: 16315–16322. 
63. Kwok CK, Marsico G, Sahakyan AB, Chambers VS, Balasubramanian S. rG4-seq 
reveals widespread formation of G-quadruplex structures in the human transcriptome. 
Nat Methods. 2016;13: 841–844. 
64. Yang SY, Lejault P, Chevrier S, Boidot R, Robertson AG, Wong JMY, et al. 
Transcriptome-wide identification of transient RNA G-quadruplexes in human cells. Nat 
Commun. 2018;9: 4730. 
65. Guo JU, Bartel DP. RNA G-quadruplexes are globally unfolded in eukaryotic cells and 
depleted in bacteria. Science. 2016;353. doi:10.1126/science.aaf5371 
66. Agarwala P, Pandey S, Mapa K, Maiti S. The G-Quadruplex Augments Translation in 
the 5′ Untranslated Region of Transforming Growth Factor β2. Biochemistry. 2013;52: 
1528–1538. 
67. Kumari S, Bugaut A, Huppert JL, Balasubramanian S. An RNA G-quadruplex in the 5’ 
UTR of the NRAS proto-oncogene modulates translation. Nat Chem Biol. 2007;3: 218–
221. 
68. Huang H, Zhang J, Harvey SE, Hu X, Cheng C. RNA G-quadruplex secondary structure 
promotes alternative splicing via the RNA-binding protein hnRNPF. Genes Dev. 
2017;31: 2296–2309. 
69. Subramanian M, Rage F, Tabet R, Flatter E, Mandel J-L, Moine H. G-quadruplex RNA 
structure as a signal for neurite mRNA targeting. EMBO Rep. 2011;12: 697–704. 
70. Rouleau S, Glouzon J-PS, Brumwell A, Bisaillon M, Perreault J-P. 3’ UTR G-
quadruplexes regulate miRNA binding. RNA. 2017;23: 1172–1179. 
71. Beaudoin J-D, Perreault J-P. Exploring mRNA 3’-UTR G-quadruplexes: evidence of 




72. Huppert JL, Bugaut A, Kumari S, Balasubramanian S. G-quadruplexes: the beginning 
and end of UTRs. Nucleic Acids Res. 2008;36: 6260–6268. 
73. Fay JC, Wyckoff GJ, Wu CI. Positive and negative selection on the human genome. 
Genetics. 2001;158: 1227–1234. 
74. Drake JA, Bird C, Nemesh J, Thomas DJ, Newton-Cheh C, Reymond A, et al. 
Conserved noncoding sequences are selectively constrained and not mutation cold 
spots. Nature Genetics. 2006. pp. 223–227. doi:10.1038/ng1710 
75. Aggarwala V, Voight BF. An expanded sequence context model broadly explains 
variability in polymorphism levels across the human genome. Nat Genet. 2016;48: 349–
355. 
76. Agarwala P, Kumar S, Pandey S, Maiti S. Human Telomeric RNA G-Quadruplex 
Response to Point Mutation in the G-Quartets. J Phys Chem B. 2015;119: 4617–4627. 
77. Resch AM, Ogurtsov AY, Rogozin IB, Shabalina SA, Koonin EV. Evolution of alternative 
and constitutive regions of mammalian 5’UTRs. BMC Genomics. 2009;10: 162. 
78. Mayr C. Evolution and Biological Roles of Alternative 3’UTRs. Trends Cell Biol. 2016;26: 
227–237. 
79. Mockenhaupt S, Makeyev EV. Non-coding functions of alternative pre-mRNA splicing in 
development. Semin Cell Dev Biol. 2015;47-48: 32–39. 
80. Brown AA, Viñuela A, Delaneau O, Spector TD, Small KS, Dermitzakis ET. Predicting 
causal variants affecting expression by using whole-genome sequencing and RNA-seq 
from multiple human tissues. Nat Genet. 2017;49: 1747–1751. 
81. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the 
human genome. Nature. 2012;489: 57–74. 
82. Li Q, Brown JB, Huang H, Bickel PJ. Measuring reproducibility of high-throughput 
experiments. The Annals of Applied Statistics. 2011. pp. 1752–1779. doi:10.1214/11-
aoas466 
83. Jourdain AA, Koppen M, Wydro M, Rodley CD, Lightowlers RN, Chrzanowska-
Lightowlers ZM, et al. GRSF1 regulates RNA processing in mitochondrial RNA 
granules. Cell Metab. 2013;17: 399–410. 
84. Pietras Z, Wojcik MA, Borowski LS, Szewczyk M, Kulinski TM, Cysewski D, et al. 
Dedicated surveillance mechanism controls G-quadruplex forming non-coding RNAs in 
human mitochondria. Nat Commun. 2018;9: 2558. 
85. Havrilla JM, Pedersen BS, Layer RM, Quinlan AR. A map of constrained coding regions 
in the human genome. Nat Genet. 2018. doi:10.1038/s41588-018-0294-6 
124 
 
86. Lord J, Gallone G, Short PJ, McRae JF, Ironfield H, Wynn EH, et al. Pathogenicity and 
selective constraint on variation near splice sites. Genome Res. 2019;29: 159–170. 
87. di Iulio J, Bartha I, Wong EHM, Yu H-C, Lavrenko V, Yang D, et al. The human 
noncoding genome defined by genetic diversity. Nat Genet. 2018;50: 333–337. 
88. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: 
public archive of relationships among sequence variation and human phenotype. 
Nucleic Acids Res. 2014;42: D980–5. 
89. Wain LV, Vaez A, Jansen R, Joehanes R, van der Most PJ, Erzurumluoglu AM, et al. 
Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association 
Study and Expression Data Sets From Blood and the Kidney. Hypertension. 2017. 
doi:10.1161/HYPERTENSIONAHA.117.09438 
90. Siitonen A, Nalls MA, Hernández D, Gibbs JR, Ding J, Ylikotila P, et al. Genetics of 
early-onset Parkinson’s disease in Finland: exome sequencing and genome-wide 
association study. Neurobiol Aging. 2017;53: 195.e7–195.e10. 
91. van de Geijn B, McVicker G, Gilad Y, Pritchard JK. WASP: allele-specific software for 
robust molecular quantitative trait locus discovery. Nat Methods. 2015;12: 1061–1063. 
92. Gros J, Rosu F, Amrane S, De Cian A, Gabelica V, Lacroix L, et al. Guanines are a 
quartet’s best friend: impact of base substitutions on the kinetics and stability of 
tetramolecular quadruplexes. Nucleic Acids Res. 2007;35: 3064–3075. 
93. Lee JY, Kim DS. Dramatic effect of single-base mutation on the conformational 
dynamics of human telomeric G-quadruplex. Nucleic Acids Res. 2009;37: 3625–3634. 
94. Garcia-Moreno M, Noerenberg M, Ni S, Järvelin AI, González-Almela E, Lenz CE, et al. 
System-wide Profiling of RNA-Binding Proteins Uncovers Key Regulators of Virus 
Infection. Mol Cell. 2019;74: 196–211.e11. 
95. Li Z, Nagy PD. Diverse roles of host RNA binding proteins in RNA virus replication. RNA 
Biol. 2011;8: 305–315. 
96. Lavezzo E, Berselli M, Frasson I, Perrone R, Palù G, Brazzale AR, et al. G-quadruplex 
forming sequences in the genome of all known human viruses: A comprehensive guide. 
PLoS Comput Biol. 2018;14: e1006675. 
97. Kikin O, D’Antonio L, Bagga PS. QGRS Mapper: a web-based server for predicting G-
quadruplexes in nucleotide sequences. Nucleic Acids Res. 2006;34: W676–82. 
98. Garant J-M, Perreault J-P, Scott MS. Motif independent identification of potential RNA 
G-quadruplexes by G4RNA screener. Bioinformatics. 2017;33: 3532–3537. 
99. Bedrat A, Lacroix L, Mergny J-L. Re-evaluation of G-quadruplex propensity with 
G4Hunter. Nucleic Acids Res. 2016;44: 1746–1759. 
125 
 
100. Fickett JW. Finding genes by computer: the state of the art. Trends in Genetics. 1996. 
pp. 316–320. doi:10.1016/0168-9525(96)10038-x 
101. Ingolia NT, Ghaemmaghami S, Newman JRS, Weissman JS. Genome-wide analysis in 
vivo of translation with nucleotide resolution using ribosome profiling. Science. 
2009;324: 218–223. 
102. Calviello L, Mukherjee N, Wyler E, Zauber H, Hirsekorn A, Selbach M, et al. Detecting 
actively translated open reading frames in ribosome profiling data. Nat Methods. 
2016;13: 165–170. 
103. Ingolia NT, Lareau LF, Weissman JS. Ribosome profiling of mouse embryonic stem 
cells reveals the complexity and dynamics of mammalian proteomes. Cell. 2011;147: 
789–802. 
104. Ji Z, Song R, Regev A, Struhl K. Many lncRNAs, 5’UTRs, and pseudogenes are 
translated and some are likely to express functional proteins. eLife. 2015. 
doi:10.7554/elife.08890 
105. Ingolia NT, Brar GA, Stern-Ginossar N, Harris MS, Talhouarne GJS, Jackson SE, et al. 
Ribosome profiling reveals pervasive translation outside of annotated protein-coding 
genes. Cell Rep. 2014;8: 1365–1379. 
106. Martinez TF, Chu Q, Donaldson C, Tan D, Shokhirev MN, Saghatelian A. Accurate 
annotation of human protein-coding small open reading frames. Nat Chem Biol. 
2020;16: 458–468. 
107. Chen J, Brunner A-D, Cogan JZ, Nuñez JK, Fields AP, Adamson B, et al. Pervasive 
functional translation of noncanonical human open reading frames. Science. 2020;367: 
1140–1146. 
108. Kastenmayer JP, Ni L, Chu A, Kitchen LE, Au W-C, Yang H, et al. Functional genomics 
of genes with small open reading frames (sORFs) in S. cerevisiae. Genome Res. 
2006;16: 365–373. 
109. Galindo MI, Pueyo JI, Fouix S, Bishop SA, Couso JP. Peptides encoded by short ORFs 
control development and define a new eukaryotic gene family. PLoS Biol. 2007;5: e106. 
110. Magny EG, Pueyo JI, Pearl FMG, Cespedes MA, Niven JE, Bishop SA, et al. Conserved 
regulation of cardiac calcium uptake by peptides encoded in small open reading frames. 
Science. 2013;341: 1116–1120. 
111. Anderson DM, Anderson KM, Chang C-L, Makarewich CA, Nelson BR, McAnally JR, et 
al. A micropeptide encoded by a putative long noncoding RNA regulates muscle 
performance. Cell. 2015;160: 595–606. 
112. Anderson DM, Makarewich CA, Anderson KM, Shelton JM, Bezprozvannaya S, Bassel-
Duby R, et al. Widespread control of calcium signaling by a family of SERCA-inhibiting 
micropeptides. Sci Signal. 2016;9: ra119. 
126 
 
113. Nelson BR, Makarewich CA, Anderson DM, Winders BR, Troupes CD, Wu F, et al. A 
peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA 
activity in muscle. Science. 2016;351: 271–275. 
114. Niu L, Lou F, Sun Y, Sun L, Cai X, Liu Z, et al. A micropeptide encoded by lncRNA 
MIR155HG suppresses autoimmune inflammation via modulating antigen presentation. 
Sci Adv. 2020;6: eaaz2059. 
115. Bhatta A, Atianand M, Jiang Z, Crabtree J, Blin J, Fitzgerald KA. A Mitochondrial 
Micropeptide Is Required for Activation of the Nlrp3 Inflammasome. J Immunol. 
2020;204: 428–437. 
116. Banerjee S, Ghoshal S, Stevens JR, McCommis KS, Gao S, Castro-Sepulveda M, et al. 
Hepatocyte expression of the micropeptide adropin regulates the liver fasting response 
and is enhanced by caloric restriction. J Biol Chem. 2020;295: 13753–13768. 
117. Spencer HL, Sanders R, Boulberdaa M, Meloni M, Cochrane A, Spiroski A-M, et al. The 
LINC00961 transcript and its encoded micropeptide, small regulatory polypeptide of 
amino acid response, regulate endothelial cell function. Cardiovasc Res. 2020;116: 
1981–1994. 
118. Zhang S, Reljić B, Liang C, Kerouanton B, Francisco JC, Peh JH, et al. Mitochondrial 
peptide BRAWNIN is essential for vertebrate respiratory complex III assembly. Nat 
Commun. 2020;11: 1312. 
119. Makarewich CA, Baskin KK, Munir AZ, Bezprozvannaya S, Sharma G, Khemtong C, et 
al. MOXI Is a Mitochondrial Micropeptide That Enhances Fatty Acid β-Oxidation. Cell 
Rep. 2018;23: 3701–3709. 
120. Matsumoto A, Pasut A, Matsumoto M, Yamashita R, Fung J, Monteleone E, et al. 
mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR 
polypeptide. Nature. 2017;541: 228–232. 
121. Ji Z, Song R, Regev A, Struhl K. Many lncRNAs, 5’UTRs, and pseudogenes are 
translated and some are likely to express functional proteins. Elife. 2015;4: e08890. 
122. Johnstone TG, Bazzini AA, Giraldez AJ. Upstream ORFs are prevalent translational 
repressors in vertebrates. EMBO J. 2016;35: 706–723. 
123. Calvo SE, Pagliarini DJ, Mootha VK. Upstream open reading frames cause widespread 
reduction of protein expression and are polymorphic among humans. Proc Natl Acad 
Sci U S A. 2009;106: 7507–7512. 
124. Chew G-L, Pauli A, Schier AF. Conservation of uORF repressiveness and sequence 
features in mouse, human and zebrafish. Nat Commun. 2016;7: 11663. 
125. Neafsey DE, Galagan JE. Dual modes of natural selection on upstream open reading 
frames. Mol Biol Evol. 2007;24: 1744–1751. 
127 
 
126. Raney A, Law GL, Mize GJ, Morris DR. Regulated translation termination at the 
upstream open reading frame in s-adenosylmethionine decarboxylase mRNA. J Biol 
Chem. 2002;277: 5988–5994. 
127. Karagyozov L, Godfrey R, Böhmer S-A, Petermann A, Hölters S, Östman A, et al. The 
structure of the 5′-end of the protein-tyrosine phosphatase PTPRJ mRNA reveals a 
novel mechanism for translation attenuation. Nucleic Acids Research. 2008. pp. 4443–
4453. doi:10.1093/nar/gkn391 
128. uAUG and uORFs in human and rodent 5′untranslated mRNAs. Gene. 2005;349: 97–
105. 
129. Shah P, Ding Y, Niemczyk M, Kudla G, Plotkin JB. Rate-Limiting Steps in Yeast Protein 
Translation. Cell. 2013. pp. 1589–1601. doi:10.1016/j.cell.2013.05.049 
130. Chan LY, Mugler CF, Heinrich S, Vallotton P, Weis K. Non-invasive measurement of 
mRNA decay reveals translation initiation as the major determinant of mRNA stability. 
Elife. 2018;7. doi:10.7554/eLife.32536 
131. LaGRANDEUR T, Parker R. The cis acting sequences responsible for the differential 
decay of the unstable MFA2 and stable PGK1 transcripts in yeast include the context of 
the translational start codon. RNA. 1999;5: 420–433. 
132. Schwartz DC, Parker R. mRNA Decapping in Yeast Requires Dissociation of the Cap 
Binding Protein, Eukaryotic Translation Initiation Factor 4E. Mol Cell Biol. 2000;20: 
7933–7942. 
133. Schwartz DC, Parker R. Mutations in Translation Initiation Factors Lead to Increased 
Rates of Deadenylation and Decapping of mRNAs inSaccharomyces cerevisiae. Mol 
Cell Biol. 1999;19: 5247–5256. 
134. Beelman CA, Parker R. Differential effects of translational inhibition in cis and in trans 
on the decay of the unstable yeast MFA2 mRNA. J Biol Chem. 1994;269: 9687–9692. 
135. Whiffin N, Karczewski KJ, Zhang X, Chothani S, Smith MJ, Gareth Evans D, et al. 
Characterising the loss-of-function impact of 5’ untranslated region variants in 15,708 
individuals. bioRxiv. 2019. p. 543504. doi:10.1101/543504 
136. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. Variation 
across 141,456 human exomes and genomes reveals the spectrum of loss-of-function 
intolerance across human protein-coding genes. bioRxiv. 2019. p. 531210. 
doi:10.1101/531210 
137. Short PJ, McRae JF, Gallone G, Sifrim A, Won H, Geschwind DH, et al. De novo 




138. Lee DSM, Ghanem LR, Barash Y. Integrative analysis reveals RNA G-quadruplexes in 
UTRs are selectively constrained and enriched for functional associations. Nat 
Commun. 2020;11: 1–12. 
139. Cridge AG, Crowe-McAuliffe C, Mathew SF, Tate WP. Eukaryotic translational 
termination efficiency is influenced by the 3’ nucleotides within the ribosomal mRNA 
channel. Nucleic Acids Res. 2018;46: 1927–1944. 
140. Loughran G, Chou M-Y, Ivanov IP, Jungreis I, Kellis M, Kiran AM, et al. Evidence of 
efficient stop codon readthrough in four mammalian genes. Nucleic Acids Res. 2014;42: 
8928–8938. 
141. Floquet C, Hatin I, Rousset J-P, Bidou L. Statistical analysis of readthrough levels for 
nonsense mutations in mammalian cells reveals a major determinant of response to 
gentamicin. PLoS Genet. 2012;8: e1002608. 
142. Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-
dependent suppression of termination codons in a mammalian translation system. RNA. 
2000;6: 1044–1055. 
143. Fearon K, McClendon V, Bonetti B, Bedwell DM. Premature translation termination 
mutations are efficiently suppressed in a highly conserved region of yeast Ste6p, a 
member of the ATP-binding cassette (ABC) transporter family. J Biol Chem. 1994;269: 
17802–17808. 
144. A direct estimation of the context effect on the efficiency of termination. J Mol Biol. 
1998;284: 579–590. 
145. Poole ES, Brown CM, Tate WP. The identity of the base following the stop codon 
determines the efficiency of in vivo translational termination in Escherichia coli. EMBO J. 
1995;14: 151–158. 
146. Bazzini AA, Johnstone TG, Christiano R, Mackowiak SD, Obermayer B, Fleming ES, et 
al. Identification of small ORFs in vertebrates using ribosome footprinting and 
evolutionary conservation. EMBO J. 2014;33: 981–993. 
147. Hanson G, Coller J. Codon optimality, bias and usage in translation and mRNA decay. 
Nat Rev Mol Cell Biol. 2018;19: 20–30. 
148. Lin Y, May GE, Kready H, Nazzaro L, Mao M, Spealman P, et al. Impacts of uORF 
codon identity and position on translation regulation. Nucleic Acids Res. 2019;47: 9358–
9367. 
149. Translational regulation of human methionine synthase by upstream open reading 




150. Fervers P, Fervers F, Makałowski W, Jąkalski M. Life cycle adapted upstream open 
reading frames (uORFs) in Trypanosoma congolense: A post-transcriptional approach 
to accurate gene regulation. PLoS One. 2018;13: e0201461. 
151. Bettany AJ, Moore PA, Cafferkey R, Bell LD, Goodey AR, Carter BL, et al. 5’-secondary 
structure formation, in contrast to a short string of non-preferred codons, inhibits the 
translation of the pyruvate kinase mRNA in yeast. Yeast. 1989;5: 187–198. 
152. Kudla G, Murray AW, Tollervey D, Plotkin JB. Coding-sequence determinants of gene 
expression in Escherichia coli. Science. 2009;324: 255–258. 
153. Wu Q, Medina SG, Kushawah G, DeVore ML, Castellano LA, Hand JM, et al. 
Translation affects mRNA stability in a codon-dependent manner in human cells. Elife. 
2019;8. doi:10.7554/eLife.45396 
154. Schulz J, Mah N, Neuenschwander M, Kischka T, Ratei R, Schlag PM, et al. Loss-of-
function uORF mutations in human malignancies. Sci Rep. 2018;8: 2395. 
155. Park J, Levin MG, Haggerty CM, Hartzel DN, Judy R, Kember RL, et al. A genome-first 
approach to aggregating rare genetic variants in LMNA for association with electronic 
health record phenotypes. Genet Med. 2020;22: 102–111. 
156. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, et al. Systematic 
comparison of phenome-wide association study of electronic medical record data and 
genome-wide association study data. Nat Biotechnol. 2013;31: 1102–1110. 
157. Diogo D, Tian C, Franklin CS, Alanne-Kinnunen M, March M, Spencer CCA, et al. 
Phenome-wide association studies across large population cohorts support drug target 
validation. Nat Commun. 2018;9: 4285. 
158. Park J, Katz N, Zhang X, Lucas AM, Verma A, Judy RL, et al. Exome-by-phenome-wide 
rare variant gene burden association with electronic health record phenotypes. bioRxiv. 
2019. p. 798330. doi:10.1101/798330 
159. Aliouat A, Hatin I, Bertin P, François P, Stierlé V, Namy O, et al. Divergent effects of 
translation termination factor eRF3A and nonsense-mediated mRNA decay factor UPF1 
on the expression of uORF carrying mRNAs and ribosome protein genes. RNA Biol. 
2020;17: 227–239. 
160. Zhang Y, Pelechano V. High-throughput 5’P sequencing reveals environmental 
regulated ribosome stalls at termination level. doi:10.1101/2020.06.22.165134 
161. Meijer HA, Thomas AAM. Ribosomes stalling on uORF1 in the Xenopus Cx41 5’ UTR 
inhibit downstream translation initiation. Nucleic Acids Res. 2003;31: 3174–3184. 
162. Fang P, Wang Z, Sachs MS. Evolutionarily conserved features of the arginine 
attenuator peptide provide the necessary requirements for its function in translational 
regulation. J Biol Chem. 2000;275: 26710–26719. 
130 
 
163. Hurt JA, Robertson AD, Burge CB. Global analyses of UPF1 binding and function reveal 
expanded scope of nonsense-mediated mRNA decay. Genome Res. 2013;23: 1636–
1650. 
164. Lee M-H. Translation repression by GLD-1 protects its mRNA targets from nonsense-
mediated mRNA decay in C. elegans. Genes Dev. 2004;18: 1047–1059. 
165. Gaba A, Jacobson A, Sachs MS. Ribosome occupancy of the yeast CPA1 upstream 
open reading frame termination codon modulates nonsense-mediated mRNA decay. 
Mol Cell. 2005;20: 449–460. 
166. Blobel G, Potter VR. Studies on free and membrane-bound ribosomes in rat liver. I. 
Distribution as related to total cellular RNA. J Mol Biol. 1967;26: 279–292. 
167. García-Cazorla À, Verdura E, Juliá-Palacios N, Anderson EN, Goicoechea L, Planas-
Serra L, et al. Impairment of the mitochondrial one-carbon metabolism enzyme SHMT2 
causes a novel brain and heart developmental syndrome. Acta Neuropathol. 2020;140: 
971–975. 
168. Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019;124: 328–350. 
169. Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun C-C, et al. Predictors of 
new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized 
clinical trials. J Am Coll Cardiol. 2011;57: 1535–1545. 
170. Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of 
incident diabetes with intensive-dose compared with moderate-dose statin therapy: a 
meta-analysis. JAMA. 2011;305: 2556–2564. 
171. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al. 
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N 
Engl J Med. 2016;375: 2144–2153. 
172. Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, et al. Association 
Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of 
Type 2 Diabetes: A Meta-analysis. JAMA. 2016;316: 1383–1391. 
173. Wen Y, Liu Y, Xu Y, Zhao Y, Hua R, Wang K, et al. Loss-of-function mutations of an 
inhibitory upstream ORF in the human hairless transcript cause Marie Unna hereditary 
hypotrichosis. Nat Genet. 2009;41: 228–233. 
174. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of 
Sociodemographic and Health-Related Characteristics of UK Biobank Participants With 
Those of the General Population. Am J Epidemiol. 2017;186: 1026–1034. 
175. Sivagnanasundaram S, Morris AG, Gaitonde EJ, McKenna PJ, Mollon JD, Hunt DM. A 
cluster of single nucleotide polymorphisms in the 5′-leader of the human dopamine D3 




176. Beffagna G, Occhi G, Nava A, Vitiello L, Ditadi A, Basso C, et al. Regulatory mutations 
in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular 
cardiomyopathy type 1. Cardiovasc Res. 2005;65: 366–373. 
177. Niesler B, Flohr T, Nöthen MM, Fischer C, Rietschel M, Franzek E, et al. Association 
between the 5’ UTR variant C178T of the serotonin receptor gene HTR3A and bipolar 
affective disorder. Pharmacogenetics. 2001;11: 471–475. 
178. Pasaje CFA, Bae JS, Park B-L, Cheong HS, Kim J-H, Uh S-T, et al. WDR46 is a 
Genetic Risk Factor for Aspirin-Exacerbated Respiratory Disease in a Korean 
Population. Allergy Asthma Immunol Res. 2012;4: 199–205. 
179. Luo E-C, Nathanson JL, Tan FE, Schwartz JL, Schmok JC, Shankar A, et al. Large-
scale tethered function assays identify factors that regulate mRNA stability and 
translation. Nat Struct Mol Biol. 2020;27: 989–1000. 
180. Ivanov IP, Loughran G, Atkins JF. uORFs with unusual translational start codons 
autoregulate expression of eukaryotic ornithine decarboxylase homologs. Proc Natl 
Acad Sci U S A. 2008;105: 10079–10084. 
181. Luukkonen BG, Tan W, Schwartz S. Efficiency of reinitiation of translation on human 
immunodeficiency virus type 1 mRNAs is determined by the length of the upstream 
open reading frame and by intercistronic distance. J Virol. 1995;69: 4086–4094. 
182. Ferreira JP, Overton KW, Wang CL. Tuning gene expression with synthetic upstream 
open reading frames. Proc Natl Acad Sci U S A. 2013;110: 11284–11289. 
183. Dvir S, Velten L, Sharon E, Zeevi D, Carey LB, Weinberger A, et al. Deciphering the 
rules by which 5’-UTR sequences affect protein expression in yeast. Proc Natl Acad Sci 
U S A. 2013;110: E2792–801. 
184. Murat P, Marsico G, Herdy B, Ghanbarian AT, Portella G, Balasubramanian S. RNA G-
quadruplexes at upstream open reading frames cause DHX36- and DHX9-dependent 
translation of human mRNAs. Genome Biol. 2018;19: 229. 
185. Wang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 
2020;19. doi:10.1038/d41573-020-00078-0 
186. Shen X, Corey DR. Chemistry, mechanism and clinical status of antisense 
oligonucleotides and duplex RNAs. Nucleic Acids Res. 2018;46: 1584–1600. 
187. Geary RS, Henry SP, Grillone LR. Fomivirsen: clinical pharmacology and potential drug 
interactions. Clin Pharmacokinet. 2002;41: 255–260. 
188. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev 
Drug Discov. 2020;19: 673–694. 
189. Kharel P, Balaratnam S, Beals N, Basu S. The role of RNA G-quadruplexes in human 
diseases and therapeutic strategies. Wiley Interdiscip Rev RNA. 2020;11: e1568. 
132 
 
190. Liang X-H, Shen W, Sun H, Migawa MT, Vickers TA, Crooke ST. Translation efficiency 
of mRNAs is increased by antisense oligonucleotides targeting upstream open reading 
frames. Nat Biotechnol. 2016;34: 875–880. 
191. Liang X-H, Shen W, Crooke ST. Specific Increase of Protein Levels by Enhancing 
Translation Using Antisense Oligonucleotides Targeting Upstream Open Frames. Adv 
Exp Med Biol. 2017;983: 129–146. 
192. Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y, et al. Translation control of the 
immune checkpoint in cancer and its therapeutic targeting. Nat Med. 2019;25: 301–311. 
193. Liang X-H, Sun H, Shen W, Wang S, Yao J, Migawa MT, et al. Antisense 
oligonucleotides targeting translation inhibitory elements in 5’ UTRs can selectively 
increase protein levels. Nucleic Acids Res. 2017;45: 9528–9546. 
194. Sasaki S, Sun R, Bui H-H, Crosby JR, Monia BP, Guo S. Steric Inhibition of 5′ UTR 
Regulatory Elements Results in Upregulation of Human CFTR. Molecular Therapy. 
2019. pp. 1749–1757. doi:10.1016/j.ymthe.2019.06.016 
195. Zamiri B, Reddy K, Macgregor RB Jr, Pearson CE. TMPyP4 porphyrin distorts RNA G-
quadruplex structures of the disease-associated r(GGGGCC)n repeat of the C9orf72 
gene and blocks interaction of RNA-binding proteins. J Biol Chem. 2014;289: 4653–
4659. 
196. Simone R, Balendra R, Moens TG, Preza E, Wilson KM, Heslegrave A, et al. G-
quadruplex-binding small molecules ameliorate FTD/ALS pathology and. EMBO Mol 
Med. 2018;10: 22–31. 
197. Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of 
genomic datasets with the R/Bioconductor package biomaRt. Nature Protocols. 2009. 
pp. 1184–1191. doi:10.1038/nprot.2009.97 
198. Durinck S, Moreau Y, Kasprzyk A, Davis S, De Moor B, Brazma A, et al. BioMart and 
Bioconductor: a powerful link between biological databases and microarray data 
analysis. Bioinformatics. 2005;21: 3439–3440. 
199. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing 
reads. EMBnet.journal. 2011;17: 10–12. 
200. Yee TW. Vector Generalized Linear and Additive Models: With an Implementation in R. 
Springer; 2015. 
201. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from 
high-throughput sequencing data. Nucleic Acids Res. 2010;38: e164. 
202. O’Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, et al. Reference 
sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and 
functional annotation. Nucleic Acids Res. 2016;44: D733–45. 
133 
 
203. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. 
REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense 
Variants. Am J Hum Genet. 2016;99: 877–885. 
204. Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for 
phenome-wide association studies in the R environment. Bioinformatics. 2014. pp. 
2375–2376. doi:10.1093/bioinformatics/btu197 
205. Price AL, Kryukov GV, de Bakker PIW, Purcell SM, Staples J, Wei L-J, et al. Pooled 
association tests for rare variants in exon-resequencing studies. Am J Hum Genet. 
2010;86: 832–838. 
 
